[{"text": "Top US Penny Stocks To Watch In January 2025 editorial-team@simplywallst.com (Simply Wall St) Fri, Jan 24, 2025, 8:04 PM 4 min read In This Article: CMCM -0.22% FDMT +5.89% HYLN -5.53% As the U.S. equities market takes a breather from its recent rally, major indices like the S&P 500 have reached new highs, reflecting investor optimism amid strong corporate earnings and pro-business policies. Despite their historical connotations, penny stocks remain an intriguing investment area due to their potential for growth when backed by robust financials. This article will explore three noteworthy penny stocks that demonstrate financial strength and offer potential opportunities for investors seeking hidden value in smaller companies. Top 10 Penny Stocks In The United States Name Share Price Market Cap Financial Health Rating QuantaSing Group (NasdaqGM:QSG) $3.08 $111.94M \u2605\u2605\u2605\u2605\u2605\u2605 BAB (OTCPK:BABB) $0.93 $6.36M \u2605\u2605\u2605\u2605\u2605\u2605 Kiora Pharmaceuticals (NasdaqCM:KPRX) $3.80 $11.61M \u2605\u2605\u2605\u2605\u2605\u2605 Inter & Co (NasdaqGS:INTR) $4.94 $2.18B \u2605\u2605\u2605\u2605\u2606\u2606 ZTEST Electronics (OTCPK:ZTST.F) $0.2899 $10.66M \u2605\u2605\u2605\u2605\u2605\u2605 Imperial Petroleum (NasdaqCM:IMPP) $2.90 $88.72M \u2605\u2605\u2605\u2605\u2605\u2605 Golden Growers Cooperative (OTCPK:GGRO.U) $4.50 $67.38M \u2605\u2605\u2605\u2605\u2605\u2605 BTCS (NasdaqCM:BTCS) $3.38 $54.13M \u2605\u2605\u2605\u2605\u2605\u2605 Smith Micro Software (NasdaqCM:SMSI) $1.26 $22.7M \u2605\u2605\u2605\u2605\u2605\u2606 CBAK Energy Technology (NasdaqCM:CBAT) $0.92 $83.39M \u2605\u2605\u2605\u2605\u2605\u2606 Click here to see the full list of 706 stocks from our US Penny Stocks screener. Let's dive into some prime choices out of the screener. 4D Molecular Therapeutics Simply Wall St Financial Health Rating: \u2605\u2605\u2605\u2605\u2605\u2605 Overview: 4D Molecular Therapeutics, Inc. is a clinical-stage biotherapeutics company that develops genetic medicines using its therapeutic vector evolution platform in the Netherlands and the United States, with a market cap of $213.11 million. Operations: The company generates revenue from its biotechnology segment, amounting to $0.017 million. Market Cap: $213.11M 4D Molecular Therapeutics, with a market cap of US$213.11 million, is a pre-revenue biotech firm focused on genetic medicines. Despite its unprofitability and forecasted earnings decline, the company has no debt and a robust cash runway exceeding three years. Recent strategic updates highlight its pipeline focus on ophthalmology with the 4D-150 program for wet AMD and DME, which aims to reduce treatment burdens significantly. While it faces challenges like being dropped from the S&P Biotechnology Select Industry Index, ongoing clinical trials and partnerships suggest potential future advancements in both ophthalmology and pulmonology sectors. Take a closer look at 4D Molecular Therapeutics' potential here in our financial health report. Learn about 4D Molecular Therapeutics' future growth trajectory here. NasdaqGS:FDMT Financial Position Analysis as at Jan 2025 Hyliion Holdings Simply Wall St Financial Health Rating: \u2605\u2605\u2605\u2605\u2605\u2606 Story Continues Overview: Hyliion Holdings Corp. develops sustainable electricity-producing technology aimed at clean and efficient energy solutions, with a market cap of $420.44 million. Operations: Hyliion Holdings Corp. has not reported specific revenue segments. Market Cap: $420.44M Hyliion Holdings Corp., with a market cap of US$420.44 million, is pre-revenue and focuses on sustainable energy solutions. Despite being unprofitable, the company has no debt and short-term assets exceeding liabilities. Recent developments include a collaboration with ElectriGen LLC to deploy its KARNO generators in the oil and gas sector, funded by a US$6 million U.S. Department of Energy grant aimed at reducing methane emissions. This initiative could create a revenue stream by utilizing excess gas while promoting environmental sustainability, though Hyliion's cash runway remains limited if historical cash flow trends persist. Dive into the specifics of Hyliion Holdings here with our thorough balance sheet health report. Examine Hyliion Holdings' earnings growth report to understand how analysts expect it to perform. NYSEAM:HYLN Debt to Equity History and Analysis as at Jan 2025 Cheetah Mobile Simply Wall St Financial Health Rating: \u2605\u2605\u2605\u2605\u2605\u2605 Overview: Cheetah Mobile Inc., with a market cap of $132.98 million, provides internet services and artificial intelligence solutions in China, Hong Kong, Japan, and internationally. Operations: The company's revenue is derived from two segments: Internet Business, which generated CN\u00a5464.75 million, and AI and Others, contributing CN\u00a5272.36 million. Market Cap: $132.98M Cheetah Mobile Inc., with a market cap of $132.98 million, operates in the internet services and AI sectors, generating revenue from its Internet Business (CN\u00a5464.75 million) and AI segments (CN\u00a5272.36 million). Despite being debt-free, the company faces challenges with unprofitability and a negative return on equity (-21.54%). Recent earnings reports reveal increased quarterly revenue to CN\u00a5192.08 million but also higher net losses of CN\u00a546.9 million compared to last year\u2019s figures, reflecting ongoing financial struggles despite some revenue growth. The seasoned management team contrasts with an inexperienced board, indicating potential strategic shifts ahead. Click to explore a detailed breakdown of our findings in Cheetah Mobile's financial health report. Learn about Cheetah Mobile's historical performance here. NYSE:CMCM Debt to Equity History and Analysis as at Jan 2025 Turning Ideas Into Actions Embark on your investment journey to our 706 US Penny Stocks selection here. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor. Want To Explore Some Alternatives? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Jump on the AI train with fast growing tech companies forging a new era of innovation. Find companies with promising cash flow potential yet trading below their fair value . This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:FDMT NYSEAM:HYLN and NYSE:CMCM . Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "FDMT", "date": "2025-01-24T17:04:55+00:00", "sentiment": {"score": 0.20245750155299902, "confidence": 0.21428819000720978, "probabilities": {"positive": 0.21428819000720978, "negative": 0.011830688454210758, "neutral": 0.7738810777664185}}, "embedding": [-0.044368304312229156, -0.0672101080417633, -0.06905138492584229, -0.0004891481949016452, 0.06637497991323471, 0.03370165079832077, 0.016272109001874924, 0.09440918266773224, 0.014857647009193897, -0.046643003821372986, -0.09001608192920685, -0.0033588893711566925, -0.04278631508350372, -0.0005182588938623667, -0.09682077169418335, -0.04720021039247513, 0.06512019038200378, -0.01712409034371376, 0.005778352729976177, 0.00339678511954844, -0.15549448132514954, -0.07518597692251205, 0.04922982677817345, 0.03806963190436363, -0.04393065348267555, 0.020843639969825745, -0.008866324089467525, 0.04488975182175636, -0.23793917894363403, -0.18076175451278687, -0.06258876621723175, 0.04653081297874451, 0.06783203780651093, -0.12216925621032715, -0.04316522926092148, -0.018881075084209442, 0.0669155865907669, 0.09168079495429993, 0.039277445524930954, -0.0413624532520771, 0.012235909700393677, -0.08762721717357635, -0.04283369705080986, 0.005413323640823364, 0.0639621913433075, -0.17017334699630737, -0.033446021378040314, 0.01776132360100746, 0.118284672498703, -0.00013493560254573822, -0.02561378851532936, 0.08036185801029205, 0.06686341017484665, 0.022131718695163727, -0.14225813746452332, 0.07776479423046112, -0.13424333930015564, -0.006668621674180031, 0.0948975533246994, -0.050014592707157135, 0.03384924679994583, -0.0026016770862042904, 0.020192386582493782, -0.0077065532095730305, 0.18282489478588104, 0.03873535245656967, -0.06273167580366135, -0.0029198843985795975, -0.013559466227889061, -0.13614407181739807, 0.04094967246055603, -0.06759033352136612, -0.12953998148441315, -0.04981280863285065, -0.09766727685928345, 0.12284669280052185, 0.0816902220249176, -0.03151698410511017, 0.06669744849205017, 0.0059215836226940155, -0.07183295488357544, -0.05132942646741867, 0.08127163350582123, -0.050615329295396805, -0.03151112422347069, 0.06027160584926605, 0.03751714527606964, 0.03539689630270004, 0.009923025965690613, -0.13037864863872528, 0.09796932339668274, 0.007224623579531908, -0.14886192977428436, 0.017963431775569916, -0.019674027338624, -0.02350533753633499, -0.06100456416606903, -0.012203725054860115, -0.06308208405971527, 0.06224723160266876, 0.2924010157585144, -0.04258167743682861, -0.09056466817855835, -0.08965843170881271, -0.015482675284147263, -0.0934717208147049, 0.10831478238105774, -0.040296465158462524, 0.04839487746357918, 0.032375846058130264, -0.016636766493320465, 0.11990193277597427, -0.07829599827528, -0.07809052616357803, -0.14259278774261475, -0.026956364512443542, -0.17697587609291077, -0.06371039897203445, 0.16664013266563416, 0.0024517029523849487, 0.06437069177627563, 0.09051404893398285, -0.11256159096956253, 0.012923827394843102, -0.05083467811346054, -0.023250887170433998, -0.05160389095544815, 1.534740999733727e-32, -0.08522690832614899, 0.11295710504055023, -0.0023501268588006496, -0.10519430786371231, -0.0645943284034729, 0.048371270298957825, 0.0783349797129631, -0.06038044020533562, -0.13747943937778473, -0.037946946918964386, -0.10755424946546555, 0.055529262870550156, -0.07031145691871643, -0.039001572877168655, -0.11175104975700378, -0.16929565370082855, 0.03747982531785965, 0.010656611062586308, 0.008541775867342949, -0.12690085172653198, -0.04017425701022148, 0.22518451511859894, -0.11934950947761536, 0.028700632974505424, 0.02672266587615013, 0.02293270453810692, -0.13186794519424438, -0.08656742423772812, 0.014704467728734016, 0.07573983073234558, -0.04338514804840088, 0.07984054088592529, 0.04575888440012932, -0.023758700117468834, -0.06387712806463242, -0.06581790000200272, -0.14030970633029938, -0.0727667585015297, 0.02975115366280079, -0.09225550293922424, -0.08706377446651459, 0.1692008078098297, -0.11075934767723083, -0.008808773010969162, -0.005367394536733627, 0.10874268412590027, -0.0975879579782486, 0.16290584206581116, 0.02041921392083168, -0.14136725664138794, -0.1684981882572174, 0.021090421825647354, -0.08635243773460388, 0.07321812212467194, -0.030007386580109596, -0.027355551719665527, 0.04223603010177612, -0.17334702610969543, 0.021337170153856277, 0.06885730475187302, 0.05872037261724472, 0.1847018003463745, -0.13679073750972748, -0.04037103429436684, -0.14548131823539734, 0.1419721394777298, 0.02016550675034523, 0.09380553662776947, -0.12192025780677795, 0.26577508449554443, -0.035131171345710754, -0.009515427984297276, 0.2694258391857147, 0.03467007726430893, 0.20438894629478455, -0.03850666061043739, 0.03967827931046486, 0.022113654762506485, 0.052736300975084305, -0.08433279395103455, 0.06460411101579666, -0.0712553933262825, -0.006307253614068031, 0.08210057765245438, -0.017059940844774246, -0.017619160935282707, -0.05568718910217285, 0.03689771518111229, -0.0186383705586195, -0.10722045600414276, 0.07628268003463745, -0.10318872332572937, 0.0592898353934288, 0.05884386599063873, -0.11954040825366974, -1.6155760728199294e-32, -0.0285366028547287, -0.005054514855146408, 0.022268403321504593, 0.021379172801971436, 0.019818538799881935, 0.04825082793831825, 0.005033111199736595, -0.09982821345329285, 0.01011417992413044, -0.04468284547328949, 0.017135515809059143, 0.0027052401565015316, -0.02056305669248104, 0.0031437159050256014, -0.030238818377256393, 0.13223184645175934, -0.0053869253024458885, -0.03770890459418297, 0.034863971173763275, -0.08549612015485764, -0.11881348490715027, 0.1215522438287735, -0.15952862799167633, 0.08316946029663086, 0.07298429310321808, 0.032879337668418884, 0.0339006707072258, 0.05194532871246338, 0.07783277332782745, 0.08007797598838806, -0.13997802138328552, 0.05268330127000809, -0.1328330636024475, 0.11205495148897171, -0.06785767525434494, 0.061915189027786255, 0.09148655831813812, -0.044586021453142166, -0.09563550353050232, 0.04958169534802437, 0.0363953597843647, -0.036007992923259735, 0.05274238809943199, 0.07636955380439758, 0.05871784687042236, 0.020076828077435493, 0.019563212990760803, 0.0006692830938845873, 0.04704979062080383, 0.18924403190612793, 0.05159178376197815, 0.07222696393728256, 0.050582870841026306, 0.09624181687831879, -0.1430446356534958, 0.03934752568602562, 0.009287809953093529, 0.0764329731464386, -0.10431089252233505, -0.08139064908027649, -0.06041577830910683, 0.15123224258422852, 0.08399933576583862, 0.10577628016471863, -0.030461613088846207, 0.018996959552168846, -0.03731950744986534, 0.13595373928546906, -0.07279715687036514, -0.14117193222045898, -0.033412955701351166, -0.05556079000234604, 0.2069597840309143, -0.2078634798526764, -0.057485006749629974, 0.20066380500793457, 0.0004375176504254341, -0.04124128073453903, 0.006895435508340597, 0.18872985243797302, -0.02138153463602066, 0.06053909286856651, 0.03366333618760109, 0.06663248687982559, 0.058743081986904144, 0.10794870555400848, 0.004752259701490402, 0.0493352897465229, -0.03760587424039841, -0.01847175881266594, 0.02720118872821331, -0.02595200203359127, 0.02109542302787304, -0.00939231552183628, -0.03979532793164253, -1.0044527698482852e-07, 0.09127773344516754, -0.12426783889532089, -0.06690199673175812, -0.04469956085085869, 0.08286000788211823, 0.01295873336493969, 0.09854534268379211, 0.03183751553297043, 0.007488620467483997, 0.20008054375648499, 0.12001057714223862, 0.09062200784683228, -0.214859277009964, -0.06034007668495178, -0.09767216444015503, -0.04650747403502464, -0.07724617421627045, 0.09548312425613403, -0.003090726211667061, -0.0011320027988404036, 0.019159968942403793, 0.12099189311265945, 0.09047552943229675, -0.09301858395338058, 0.014525042846798897, 0.005115855950862169, -0.045053135603666306, -0.020970778539776802, 0.08264029771089554, 0.05784894526004791, -0.012950832024216652, 0.0182948000729084, 0.04063037037849426, -0.050303976982831955, 0.1324175000190735, 0.0620085671544075, -0.034307196736335754, 0.14279118180274963, -0.01907491683959961, 0.08224210143089294, -0.04763872176408768, -0.12545989453792572, -0.032677531242370605, -0.0087195485830307, 0.06188046559691429, -0.1240701973438263, -0.11049816012382507, 0.008666511625051498, 0.17678263783454895, -0.22040152549743652, -0.0672021359205246, -0.033938001841306686, -0.01068788766860962, -0.009635590016841888, 0.053214605897665024, 0.18269650638103485, -0.17971216142177582, 0.023744992911815643, -0.0978018194437027, -0.059371497482061386, 0.08578962832689285, -0.27446895837783813, 0.07153794169425964, 0.18682345747947693], "changes": {"1wk": 20.171675708154364}}, {"text": "PREMIUM BMO Capital Downgrades 4D Molecular Therapeutics to Market Perform From Outperform, Adjusts Price Target to $15 From $40 MT Newswires Mon, Jan 13, 2025, 3:23 PM In This Article: FDMT +5.89% 4D Molecular Therapeutics (FDMT) has an average rating of overweight and mean price target of $37.20 PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "FDMT", "date": "2025-01-13T12:23:36+00:00", "sentiment": {"score": 0.058896683156490326, "confidence": 0.07234678417444229, "probabilities": {"positive": 0.07234678417444229, "negative": 0.013450101017951965, "neutral": 0.9142031073570251}}, "embedding": [0.03698045387864113, -0.11664996296167374, -0.03894203156232834, 0.05895979702472687, 0.14810101687908173, -0.021184230223298073, -0.017704498022794724, 0.3709551692008972, 0.06904005259275436, 0.13449448347091675, -0.0358666330575943, 0.044789306819438934, -0.038635723292827606, 0.08999345451593399, 0.07158717513084412, 0.05603521317243576, 0.07136980444192886, 0.02702716737985611, -0.03112129308283329, 0.11971183866262436, -0.15029509365558624, 0.04547089338302612, 0.1491825431585312, 0.08636520802974701, 0.03929401934146881, -0.06813088804483414, 0.036114148795604706, -0.11456741392612457, 0.0009119248716160655, -0.04896511882543564, -0.10903609544038773, 0.016841765493154526, 0.0803418681025505, -0.1262308955192566, -0.0375671461224556, -0.07823054492473602, -0.1372755467891693, 0.03281649574637413, -0.13702237606048584, -0.00358182773925364, 0.004706254694610834, 0.0019305903697386384, -0.18707184493541718, 0.05962194502353668, -0.042228519916534424, -0.16196179389953613, -0.07792872935533524, 0.1352676898241043, 0.12914250791072845, 0.20138466358184814, 0.037481632083654404, -0.0832584872841835, -0.07440167665481567, 0.03205209970474243, -0.012386150658130646, -0.018249697983264923, -0.23720845580101013, -0.08626922965049744, 0.008743589743971825, 0.06189284101128578, 0.01149702351540327, 0.004693280439823866, -0.1825483739376068, -0.023122569546103477, 0.24162301421165466, 0.2011074274778366, 0.06549440324306488, -0.006574252154678106, -0.017177384346723557, -0.026670586317777634, 0.04177212342619896, 0.0409465953707695, 0.14124548435211182, -0.021914510056376457, 0.058713700622320175, 0.08910641074180603, 0.04451045021414757, -0.0305873341858387, 0.003704191418364644, 0.0432354211807251, 0.15555456280708313, -0.07130340486764908, 0.14677031338214874, -0.030816754326224327, 0.12446080148220062, -0.04535100609064102, 0.013112720102071762, 0.051365721970796585, -0.006351756397634745, 0.02813883125782013, 0.08886123448610306, 0.05427728220820427, -0.08936584740877151, -0.0338023379445076, -0.29519951343536377, 0.018345141783356667, -0.14011898636817932, -0.04126623272895813, -0.010600864887237549, 0.0124387601390481, 0.026150118559598923, -0.018746118992567062, -0.16487877070903778, 0.015436936169862747, -0.0661916509270668, -0.11887867003679276, 0.10882721096277237, 0.05322885885834694, 0.03950417414307594, 0.03500232473015785, -0.06403892487287521, 0.09653807431459427, 0.06734326481819153, -0.08472970128059387, -0.10022906959056854, 0.16793318092823029, -0.07890158146619797, -0.03565823659300804, 0.09873214364051819, 0.036295462399721146, -0.08802564442157745, 0.03035718761384487, -0.006628860719501972, -0.10364078730344772, -0.09521153569221497, -0.13503491878509521, -0.21101321280002594, 1.5005890684856993e-32, 0.06496308743953705, 0.15021899342536926, 0.06404043734073639, -0.019399579614400864, -0.049166031181812286, 0.0847463607788086, 0.08474138379096985, -0.12131154537200928, -0.2373562604188919, -0.07425960898399353, -0.08759543299674988, -0.022904450073838234, -0.0691983550786972, 0.045181483030319214, -0.08915690332651138, -0.2604834735393524, 0.035670191049575806, 0.08202149718999863, 0.21033449470996857, -0.00983963068574667, -0.00018812016060110182, 0.0695471242070198, -0.11747848987579346, -0.039514970034360886, -0.05496574193239212, 0.11488644033670425, 0.06170444190502167, 0.12316516041755676, 0.2036157101392746, 0.07377586513757706, -0.33559244871139526, 0.11361700296401978, -0.0428914912045002, -0.13631191849708557, 0.054243989288806915, -0.035229604691267014, -0.1143980547785759, -0.10573118180036545, -0.02641826868057251, -0.1261274814605713, -0.047035180032253265, 0.08245804160833359, -0.20921331644058228, -0.18534602224826813, 0.0658758357167244, 0.15163059532642365, -0.094187431037426, -0.10853693634271622, -0.057731468230485916, 0.018664192408323288, -0.0471203587949276, 0.10738267749547958, -0.15333524346351624, 0.08954527974128723, -0.16547170281410217, -0.08884737640619278, -0.17684246599674225, -0.1894298791885376, 0.05887842923402786, 0.24460850656032562, 0.1718791127204895, 0.08645018935203552, -0.016641857102513313, 0.010595319792628288, -0.13295984268188477, 0.10276389867067337, -0.13961556553840637, -0.1201266348361969, -0.1100185364484787, 0.19361793994903564, 0.1579577922821045, 0.016456402838230133, 0.1717936247587204, -0.1611517369747162, 0.11341618001461029, 7.148126314859837e-05, 0.052584029734134674, -0.059636812657117844, 0.11370240896940231, 0.02167358249425888, 0.028441978618502617, 0.005257450044155121, -0.09290644526481628, 0.04024637117981911, 0.019718602299690247, -0.08990316092967987, -0.09303855150938034, -0.025138383731245995, -0.014207395724952221, -0.06007070094347, 0.14547717571258545, -0.3129614293575287, -0.1431034356355667, 0.03481828048825264, -0.01087502483278513, -1.4700085829490575e-32, -0.0824018195271492, 0.03213202953338623, 0.1219012662768364, -0.01068843249231577, -0.06150827929377556, 0.020512664690613747, 0.04496392235159874, 0.1813686043024063, 0.27125510573387146, 0.171738401055336, 0.08830536156892776, 0.06996697187423706, -0.16768108308315277, 0.14013546705245972, 0.012983839027583599, 0.08996045589447021, -0.07705894112586975, -0.2670982778072357, 0.04423590004444122, -0.042841970920562744, -0.04735032841563225, 0.15921448171138763, -0.04409249871969223, 0.29251670837402344, 0.08847031742334366, 0.11508914083242416, 0.021946055814623833, 0.19486816227436066, 0.1318959891796112, 0.015352856367826462, -0.14927896857261658, 0.037907782942056656, -0.1531856656074524, 0.03825603425502777, -0.16529828310012817, 0.06343112885951996, 0.2353609949350357, 0.08046598732471466, -0.04172812029719353, -0.09575524181127548, -0.003043074393644929, 0.05486935377120972, -0.01809694431722164, -0.07226764410734177, 0.16552525758743286, -0.031217604875564575, 0.012885084375739098, -0.08690237998962402, 0.24010564386844635, -0.015239215455949306, -0.04389049857854843, 0.024323832243680954, 0.06906881183385849, -0.017871888354420662, -0.2989688217639923, -0.17053134739398956, 0.06766639649868011, 0.10107069462537766, -0.027665240690112114, 0.07581719011068344, 0.01694302260875702, 0.11439158767461777, -0.07003152370452881, 0.008808574639260769, -0.05426069721579552, -0.0018132547847926617, 0.17372503876686096, -0.05845145508646965, 0.07869207859039307, -0.012956245802342892, -0.052283842116594315, -0.08724800497293472, 0.18180768191814423, -0.00980723462998867, 0.09988652169704437, 0.10442286729812622, 0.1400286704301834, -0.10229755192995071, -0.07577408105134964, 0.09070610255002975, 0.08648103475570679, -0.03830462321639061, -0.013367078267037868, -0.03788365051150322, -0.10302507877349854, -0.1404716968536377, 0.17454810440540314, -0.03700660541653633, -0.18528199195861816, 0.049441564828157425, -0.08985036611557007, -0.023390093818306923, 0.07586448639631271, 0.10993777960538864, 0.14071215689182281, -1.0044874443337903e-07, 0.04591454565525055, -0.09098432958126068, -0.018489867448806763, 0.0381549634039402, 0.06363774091005325, 0.011004341766238213, -0.03719593212008476, 0.04565223306417465, 0.07426618039608002, 0.10395531356334686, -0.14349642395973206, 0.06484874337911606, -0.16062000393867493, -0.04855078458786011, -0.1182524561882019, -0.021181786432862282, -0.14404983818531036, -0.04165678471326828, 0.004357066936790943, -0.14091964066028595, -0.07513285428285599, 0.1676720380783081, 0.04784855246543884, -0.03876573219895363, -0.05551031976938248, 0.06343726813793182, -0.023102784529328346, -0.03983141481876373, 0.1159868836402893, 0.07808341085910797, -0.02430238202214241, 0.04101014509797096, 0.006399577017873526, 0.03512813150882721, -0.07516569644212723, -0.13833418488502502, -0.04793941602110863, 0.08694751560688019, -0.12826862931251526, 0.18745698034763336, 0.02702433429658413, -0.09129123389720917, -0.06725805997848511, 0.01403742004185915, -0.05342887341976166, -0.017656899988651276, -0.24554848670959473, 0.03503693640232086, 0.16857397556304932, -0.15488550066947937, 0.15833497047424316, -0.016547320410609245, -0.05808323621749878, -0.06412743777036667, -0.09167318791151047, 0.05019646883010864, -0.1348026692867279, 0.0632062628865242, -0.14111150801181793, -0.06184116378426552, 0.008791802451014519, -0.40455904603004456, 0.060853488743305206, 0.08259257674217224], "changes": {"1wk": -3.7815188344657877}}, {"text": "PREMIUM 4D Molecular Therapeutics to Focus Pipeline on Wet AMD, Cystic Fibrosis Drug Candidates MT Newswires Fri, Jan 10, 2025, 4:53 PM In This Article: FDMT +5.89% 4D Molecular Therapeutics (FDMT) said Friday that it will focus on two product candidates: 4D-150 fo PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "FDMT", "date": "2025-01-10T13:53:56+00:00", "sentiment": {"score": 0.06044176407158375, "confidence": 0.07132312655448914, "probabilities": {"positive": 0.07132312655448914, "negative": 0.010881362482905388, "neutral": 0.9177955389022827}}, "embedding": [-0.028174148872494698, -0.12518776953220367, 0.05944925546646118, -0.11834241449832916, 0.1769523024559021, -0.05758516862988472, -0.08440883457660675, 0.290432333946228, 0.020265186205506325, 0.0595799945294857, -0.012275179848074913, 0.09113703668117523, -0.04259597882628441, 0.23442210257053375, -0.08984719216823578, 0.11208051443099976, 0.030320655554533005, 0.059419501572847366, -0.02339383214712143, 0.03388265520334244, -0.1165456548333168, -0.009114059619605541, 0.1452719122171402, -0.07580875605344772, -0.14931434392929077, -0.006257344037294388, -1.656436870689504e-05, -0.11068166792392731, -0.018661441281437874, 0.000492921331897378, 0.011319400742650032, 0.13426759839057922, 0.07750360667705536, -0.11646316200494766, 0.04490004852414131, -0.06838082522153854, -0.03584297001361847, -0.10635897517204285, -0.08544380217790604, -0.01536608301103115, 0.055578600615262985, -0.13981950283050537, -0.014155848883092403, 0.16239485144615173, 0.04873022437095642, -0.15701857209205627, -0.07741891592741013, 0.008923852816224098, 0.11131879687309265, 0.08768515288829803, 0.04174421727657318, -0.11809826642274857, -0.01494334265589714, 0.07393374294042587, -0.03196791931986809, 0.023780211806297302, -0.3069186508655548, -0.15341176092624664, -0.08076075464487076, 0.062011729925870895, 0.07867708057165146, -0.01390970777720213, -0.1375746876001358, 0.09764501452445984, 0.2310440093278885, 0.2001350075006485, 0.010069886222481728, 0.0297574270516634, -0.032691795378923416, -0.1029113307595253, -0.10610294342041016, 0.11077841371297836, 0.09387291222810745, 0.009160907007753849, 0.13742831349372864, 0.08017116039991379, 0.10641536861658096, -0.03965049237012863, 0.04599840193986893, -0.006550735328346491, 0.12888720631599426, 0.018903953954577446, 0.21928644180297852, -0.18781748414039612, 0.13277070224285126, 0.05869242176413536, -0.006900714710354805, -0.05069565027952194, -0.10265882313251495, -0.03485779091715813, 0.05525733903050423, 0.019906289875507355, -0.08101564645767212, 0.054784152656793594, -0.2835952639579773, 0.05835650488734245, -0.05023159086704254, -0.06477771699428558, -0.040746428072452545, 0.020865142345428467, -0.09012342989444733, -0.009476747363805771, -0.03653295338153839, -0.07553248852491379, -0.05318973585963249, -0.19594086706638336, 0.14913183450698853, 0.11172747611999512, -0.09879826754331589, -0.00537342531606555, -0.09978093206882477, 0.04799312725663185, 0.0661093071103096, -0.06728268414735794, -0.04451260343194008, 0.16474363207817078, -0.16233104467391968, 0.04044416919350624, 0.1839209944009781, 0.015685930848121643, -0.14331138134002686, 0.013257901184260845, 0.01256877463310957, -0.026090482249855995, 0.07207263261079788, 0.015666894614696503, -0.21921390295028687, 1.514481207660511e-32, 0.08684432506561279, 0.13829612731933594, 0.11466266214847565, 0.13208410143852234, 0.013169617392122746, 0.028384430333971977, 0.07696498930454254, -0.2242094725370407, -0.15315450727939606, -0.12030890583992004, -0.12050949782133102, 0.004159075673669577, -0.04672090709209442, 0.06016266718506813, -0.1464151293039322, -0.2479548305273056, 0.05297766253352165, 0.04416291043162346, 0.13194939494132996, -0.060221776366233826, 0.09323189407587051, 0.14956334233283997, -0.022609885782003403, -0.004538240376859903, 0.07637829333543777, 0.0512225441634655, -0.013414441607892513, 0.19366203248500824, 0.23209024965763092, 0.13806289434432983, -0.3923424184322357, 0.07920132577419281, -0.020942021161317825, -0.16118749976158142, -0.002252205740660429, 0.07688377797603607, -0.1572125256061554, -0.17383645474910736, -0.010457752272486687, -0.07913950085639954, -0.11375867575407028, -0.0006908178329467773, -0.11490687727928162, -0.19645866751670837, 0.06622465699911118, 0.04958810284733772, -0.1924101561307907, -0.04479825869202614, -0.03775500878691673, -0.024809781461954117, 0.06467080861330032, 0.11001822352409363, -0.12945708632469177, -0.017084144055843353, -0.08330812305212021, -0.20548459887504578, -0.21782706677913666, -0.14283984899520874, 0.09854148328304291, 0.20988880097866058, 0.08897946774959564, 0.07616228610277176, -0.13065491616725922, 0.0021219244226813316, -0.13981813192367554, -0.0008666754001751542, -0.0073385038413107395, -0.14526446163654327, -0.13935592770576477, 0.3040247857570648, 0.04139281064271927, -0.018375299870967865, 0.16080503165721893, -0.10248967260122299, 0.27111005783081055, -0.03450440242886543, 0.07014121860265732, -0.032106779515743256, 0.04260406643152237, -0.0409630686044693, -0.016320202499628067, 0.03323175013065338, -0.0896303653717041, 0.18778377771377563, 0.061324406415224075, -0.11382005363702774, 0.0012053265236318111, 0.0517941378057003, 0.05447356775403023, -0.04989616572856903, 0.10505128651857376, -0.1796640008687973, 0.01238839328289032, 0.10242681205272675, 0.014795193448662758, -1.6186502844209173e-32, -0.03112012706696987, 0.09932561218738556, 0.004834677092730999, -0.03800460323691368, -0.027679981663823128, 0.11802418529987335, 0.10348492115736008, 0.1144690066576004, 0.2739012837409973, -0.010296163149178028, 0.1592290699481964, -0.021890155971050262, -0.13066619634628296, -0.028011709451675415, -0.05443716049194336, 0.1220930889248848, -0.16434839367866516, -0.3854749798774719, -0.054944057017564774, 0.13288506865501404, -0.0030398282688111067, 0.07238345593214035, -0.04104769229888916, 0.19216956198215485, 0.06539198011159897, 0.08797478675842285, 0.08478543907403946, 0.07439078390598297, -0.06807328760623932, 0.029901953414082527, -0.17470459640026093, 0.02967890165746212, -0.19621685147285461, 0.03990812227129936, -0.132029727101326, 0.015796281397342682, 0.2529527544975281, -0.0030860500410199165, -0.09032879769802094, -0.10776521265506744, 0.06699391454458237, -0.01987370289862156, -0.014170000329613686, 0.05244850367307663, 0.03914163261651993, 0.14953681826591492, 0.07709664851427078, -0.04663824290037155, 0.2181033492088318, -0.024016598239541054, -0.08926063776016235, 0.07552020251750946, 0.004701885394752026, -0.008569401688873768, -0.14447665214538574, -0.0531434640288353, 0.1357126533985138, -0.05409850552678108, -0.0935022160410881, 0.0973631888628006, -0.08981259912252426, 0.00024172544362954795, 0.004679929930716753, -0.1026337593793869, 0.08293221145868301, -0.02344752848148346, 0.12433933466672897, 0.012407557107508183, 0.015198261477053165, 0.047810960561037064, -0.09530866891145706, -0.08423956483602524, 0.039949480444192886, -0.009531005285680294, 0.10328353941440582, 0.04661126434803009, 0.03823280707001686, -0.12262611091136932, -0.15384845435619354, 0.17369461059570312, 0.08312497287988663, -0.04634002223610878, -0.1028585210442543, 0.07529590278863907, 0.02043558843433857, -0.07172209769487381, 0.21500445902347565, -0.11374471336603165, -0.07066326588392258, -0.05542812496423721, -0.021256310865283012, 0.07872164249420166, -0.07645872980356216, 0.16498292982578278, 0.1107056587934494, -1.0032406549953521e-07, 0.055194418877363205, -0.03950617089867592, -0.030072906985878944, -0.12489331513643265, 0.018167823553085327, 0.03498160466551781, -0.08142359554767609, 0.1542251855134964, 0.01451218780130148, 0.029843347147107124, -0.08919210731983185, 0.16161182522773743, -0.06608488410711288, 0.004366124980151653, 0.07697440683841705, 0.0041238730773329735, -0.1283692717552185, -0.09203316271305084, -0.0669962540268898, -0.22830462455749512, -0.14868713915348053, 0.10849238932132721, 0.06424667686223984, 0.06426403671503067, -0.09052229672670364, -0.020383208990097046, 0.06498967856168747, -0.08117125928401947, 0.025396594777703285, -0.019232353195548058, 0.013258489780128002, 0.06521820276975632, -0.045581985265016556, 0.04877103120088577, -0.1598663330078125, -0.08553338795900345, 0.014270223677158356, 0.0768393874168396, -0.0906687080860138, 0.2941025197505951, -0.009382662363350391, -0.007649495266377926, -0.03911620005965233, 0.031922340393066406, -0.06855190545320511, -0.11029507964849472, -0.04131646081805229, -0.09772639721632004, 0.04494986683130264, -0.052328020334243774, -0.0244513601064682, -0.0956408828496933, 0.024795014411211014, -0.05327024310827255, -0.03225657343864441, 0.15285944938659668, -0.13935144245624542, 0.01331520639359951, -0.04226012900471687, -0.08783935755491257, -0.04224179685115814, -0.3047966957092285, 0.15490202605724335, 0.10685834288597107], "changes": {"1wk": -15.217394121202505}}, {"text": "4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway 4D Molecular Therapeutics, Inc. Fri, Jan 10, 2025, 4:00 PM 8 min read In This Article: FDMT +5.89% 4D Molecular Therapeutics, Inc. Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 for wet AMD and DME and 4D-710 for cystic fibrosis After alignment with FDA and EMA on trial designs for the 4D-150 Phase 3 4FRONT program in wet AMD, 4FRONT-1 and 4FRONT-2 trials on track to initiate in Q1 2025 and Q3 2025 respectively Primary endpoint 52-week topline data for both 4FRONT-1 and 4FRONT-2 expected in H2 2027 Cash runway extended under updated operating plan; unaudited cash, cash equivalents and marketable securities of $506M as of December 31, 2024 expected to fund operations into 2028 EMERYVILLE, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics\u00a0(Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced a strategically focused pipeline, updated Phase 3 4FRONT program plans, initial 4FRONT guidance and resulting updated cash runway guidance. \u201c4DMT was founded to address the challenges posed by traditional AAVs and to bring genetic medicines to market to transform outcomes for millions of patients. Over 10 years we created a diverse pipeline to bring this vision closer to reality with seven named product candidates across three therapeutic areas utilizing three novel, clinically-validated vectors,\u201d said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. \u201cWe have prioritized two product candidates with the strongest clinical proof of concept and high potential to impact the most patients to fulfil our mission. In addition, our ongoing regulatory interactions support an efficient path to Biologics License Applications (BLA) for 4D-150 in both wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).\u201d Strategically Focused Pipeline Core Programs: Updates & Upcoming Milestones Large Market Ophthalmology Focus 4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) targeted to the retina with a single, well tolerated, intravitreal injection. 4D-150 is being developed for wet AMD and DME, each of which affects millions of patients globally, with the goal of preserving vision and relieving patients from burdensome repeated bolus injections, which can total up to 12 per year. 4DMT will focus the majority of its R&D resources and operations on global development and pre-commercial planning for 4D-150 in wet AMD. Story Continues 4D-150 for Wet AMD: Ongoing Phase 1/2 PRISM clinical trial currently in long-term follow-up: 52-week interim data from Phase 2b cohort of the PRISM clinical trial to be presented at Angiogenesis, Exudation, and Degeneration 2025 on Saturday, February 8, 2025 Corporate webcast to discuss data to be held on Monday, February 10, 2025 Phase 3 4FRONT program overview and updates: Trial designs and CMC plans aligned with U.S. Food & Drug Administration (FDA) under RMAT designation and European Medicines Agency (EMA) under PRIME designation, based on multiple interactions through December 2024 4FRONT-1 and 4FRONT-2 are on target to initiate in Q1 and Q3 2025, respectively 4FRONT-1 and 4FRONT-2 clinical trial design: Primary endpoint: best corrected visual acuity (BCVA) noninferiority of 4D-150 3E10 vg/eye to aflibercept 2mg Q8W Enrichment criteria: Randomization requires on study demonstration of aflibercept responsiveness Supplemental aflibercept injection criteria for 4D-150 arm optimized to protect primary BCVA endpoint and to maximize reduction of supplemental treatment burden; criteria to be disclosed prior to trial initiation. No supplemental injections allowed in control arm Target enrollment of 400 patients per trial Designed with \u226590% power for primary endpoint of BCVA noninferiority of 4D-150 versus aflibercept 2mg Q8 weeks (margin of 4.5 letters) and supports required program safety database for BLA submission 4FRONT-1 to enroll treatment na\u00efve population and 4FRONT-2 to enroll both treatment na\u00efve and previously treated population, diagnosed within the last six months Primary endpoint 52-week topline data from both 4FRONT-1 and 4FRONT-2 expected in H2 2027 4D-150 for DME: Ongoing SPECTRA Part 1 follow-up continues: Announced positive 32-week interim data today in separate press release Results and next steps to be presented in a corporate webcast on February 10, 2025 52-week interim data update expected at a scientific conference in mid-2025 Announced regulatory update, in separate press release issued today, summarizing written FDA feedback. Based on review of SPECTRA and PRISM data to date, combined with data from the two planned Phase 3 clinical trials in the 4FRONT wet AMD program, a single Phase 3 trial of 300-400 patients is acceptable for BLA submission and the Company may directly proceed into Phase 3 (SPECTRA Part 2 no longer needed) Pulmonology Program 4DMT\u2019s proprietary A101 vector is the first known AAV vector to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis (CF) following aerosol delivery. Given A101-enabled product candidate 4D-710\u2019s proof of delivery, safety data and initial clinical activity signals, and ongoing support from the Cystic Fibrosis Foundation and collaboration with Therapeutics Development Network,\u00a0the Company intends to complete Phase 1 enrollment in H1 2025, approach the FDA with a pivotal trial proposal mid-2025, and evaluate additional funding options to further advance 4D-710 into late-stage development. 4D-710 for CF Lung Disease: Phase 1 AEROW enrollment completed in November 2024 (Cohorts 3 & 4 fully enrolled with n=3 each), follow-up ongoing; trial allows up to an additional 3 people with CF at these dose levels Interim data update expected to be presented in mid-2025 at a scientific conference, including available measurements of ppFEV 1 , CFQ-R-R (quality-of-life instrument), lung clearance index and serial airway biopsies and brushings collected at 4-8 weeks and beyond 12 months post-dosing Programs with Reduced Capital Allocation While we believe the therapeutics below hold significant potential, at this time no further significant investment is expected on these programs, pending additional financing or partnerships. 4D-175 for geographic atrophy (preclinical with open IND) 4D-725 for alpha-1-antitrypsin deficiency lung disease (preclinical) 4D-310 for Fabry disease cardiomyopathy (ongoing Phase 1) Following a comprehensive review of its portfolio, the Company has decided to terminate the development of the early-stage rare disease clinical programs evaluating 4D-110 for choroideremia and 4D-125 for X-linked retinitis pigmentosa. Given the promising portfolio of product candidates and vectors owned and developed by 4DMT, 4DMT will not be investing additional capital into new preclinical product candidates at this time. Updated Financial Guidance As a result of its strategically focused pipeline, resource reallocation and discontinued future investment plans on non-core product candidates, the Company has extended its cash runway. Under the updated operating plan, based on unaudited cash, cash equivalents and marketable securities of $506M as of December 31, 2024,\u00a0the Company now expects its current cash to fund operations into 2028. Cash runway includes full execution and topline 52-week data from 4FRONT-1 and 4FRONT-2 Phase 3 clinical trials in wet AMD, and ongoing early-stage development for DME and CF. Additionally, the Company will explore value-creating partnership opportunities and other strategic financing options. About 4DMT 4DMT is a late-stage biotechnology company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT\u2019s proprietary invention platform, Therapeutic Vector Evolution, combines the power of directed evolution with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our lead program 4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) targeted to the retina with a single, safe, intravitreal injection. Our second core program is 4D-710, which is the first known genetic medicine to demonstrate, in the lungs of people with cystic fibrosis (CF), successful delivery and expression of the CFTR transgene and initial clinical activity signals after aerosol delivery of a gene therapy. 4D Molecular Therapeutics\u2122, 4DMT\u2122, Therapeutic Vector Evolution\u2122, and the 4DMT logo are trademarks of 4DMT. All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the FDA or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied. Learn more at www.4DMT.com and follow us on LinkedIn . Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the therapeutic potential, and clinical benefits and market potential of 4DMT\u2019s product candidates, as well as the plans, announcements, and related timing for the clinical development of, regulatory interactions regarding, and potential commercialization of our product candidates, including 4D-150 and 4D-710, and statements regarding our anticipated resource allocation and cash runway. The words \"may,\" \u201cmight,\u201d \"will,\" \"could,\" \"would,\" \"should,\" \"expect,\" \"plan,\" \"anticipate,\" \"intend,\" \"believe,\" \u201cexpect,\u201d \"estimate,\" \u201cseek,\u201d \"predict,\" \u201cfuture,\u201d \"project,\" \"potential,\" \"continue,\" \"target\" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including risks and uncertainties that are described in greater detail in the section entitled \"Risk Factors\" in 4D Molecular Therapeutics\u2019 most recent Quarterly Report on Form 10-Q as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent 4D Molecular Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. 4D Molecular Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward looking statements. Contacts: Media: Katherine Smith Inizio Evoke Comms Media@4DMT.com Investors: Julian Pei Head of Investor Relations and Corporate Finance Investor.Relations@4DMT.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "FDMT", "date": "2025-01-10T13:00:00+00:00", "sentiment": {"score": 0.755330353975296, "confidence": 0.7629239559173584, "probabilities": {"positive": 0.7629239559173584, "negative": 0.007593601942062378, "neutral": 0.22948254644870758}}, "embedding": [-0.03996869921684265, -0.06914670765399933, 0.07340444624423981, -0.19605877995491028, -0.041882455348968506, -0.11783459782600403, -0.13617192208766937, 0.20030775666236877, 0.08399011939764023, 0.1304074376821518, -0.16473086178302765, 0.05744393542408943, -0.07155323028564453, 0.11286592483520508, -0.1097722202539444, 0.09902466833591461, -0.0868990495800972, 0.07974499464035034, -0.15181124210357666, 0.041093744337558746, 0.04872407391667366, 0.030091669410467148, 0.09498928487300873, -0.01437339372932911, -0.12254440784454346, -0.022945543751120567, -0.0145876444876194, -0.09111782908439636, -0.11534597724676132, -0.10443070530891418, 0.12435894459486008, 0.1997925043106079, 0.05165139585733414, -0.10510537028312683, -0.012944566085934639, 0.024736426770687103, -0.02620198205113411, -0.050357885658741, -0.12997469305992126, -0.03053981065750122, 0.024461131542921066, -0.03688032925128937, -0.09204527735710144, 0.19783669710159302, 0.13243091106414795, -0.18068835139274597, -0.10584336519241333, -0.004434775561094284, 0.0766163095831871, 0.11201314628124237, -0.0319916233420372, -0.07022618502378464, -0.07421476393938065, 0.12230941653251648, -0.06120288372039795, 0.08174582570791245, -0.12521681189537048, -0.01692788675427437, 0.0329250805079937, 0.058445341885089874, 0.09701736271381378, -0.06250520050525665, -0.018396766856312752, -0.006350645795464516, 0.1519700586795807, 0.09555819630622864, 0.003060759976506233, -0.044465795159339905, -0.07327722012996674, -0.12504759430885315, 0.06584946066141129, -0.033517204225063324, 0.02658088505268097, 0.0018392838537693024, 0.030102422460913658, 0.13569609820842743, 0.15424738824367523, 0.11342999339103699, 0.0877375602722168, -0.11112047731876373, 0.1408727765083313, 0.07256286591291428, 0.17497195303440094, -0.13897229731082916, 0.021154308691620827, 0.07843989133834839, -0.07796050608158112, 0.02445458620786667, 0.05410943925380707, 0.028569603338837624, -0.04384908825159073, -0.0783584713935852, -0.03512111306190491, 0.04576028883457184, -0.07026783376932144, 0.04215089604258537, -0.013341913931071758, -0.11349989473819733, 0.11357413232326508, 0.02724541537463665, 0.01406768523156643, 0.004782425239682198, -0.07527127116918564, -0.06767675280570984, -0.005948629695922136, -0.17126771807670593, 0.1813405603170395, -0.031077463179826736, -0.07074102759361267, -0.08373929560184479, -0.07149454951286316, 0.021277526393532753, 0.06688692420721054, 0.04767759516835213, -0.13109073042869568, 0.19944573938846588, -0.1008659228682518, 0.052188608795404434, 0.19225367903709412, -0.030922455713152885, -0.07386036217212677, 0.049207206815481186, 0.07781322300434113, -0.12732535600662231, 0.08274611830711365, 0.05211148411035538, -0.11598830670118332, 1.2141921391301357e-32, 0.011788289994001389, -0.021277200430631638, 0.0729089006781578, 0.1310518980026245, 0.010510677471756935, -0.06807583570480347, 0.08947733044624329, -0.05269920825958252, -0.23984059691429138, -0.09155909717082977, -0.09993229806423187, -0.021800437942147255, -0.0429309606552124, 0.16878372430801392, -0.09831826388835907, -0.23332417011260986, 0.008619002066552639, 0.030142061412334442, 0.032175831496715546, -0.05769708752632141, 0.03604506328701973, 0.06732611358165741, -0.061696454882621765, 0.020557232201099396, 0.06901133060455322, 0.06368643045425415, -0.052579089999198914, 0.1276286542415619, 0.1557948887348175, 0.09096682816743851, -0.31993210315704346, 0.06500855833292007, 0.0878600925207138, -0.15121039748191833, -0.04863971471786499, -0.02913581021130085, -0.040573850274086, -0.17202749848365784, 0.06436864286661148, 0.08839264512062073, -0.06825782358646393, 0.030142588540911674, -0.021700195968151093, -0.20178282260894775, 0.0348527692258358, 0.007208561059087515, -0.08290369808673859, -0.026683364063501358, -0.08937244862318039, 0.09768573939800262, 0.007997144013643265, 0.048100829124450684, 0.05732434242963791, -0.04479195922613144, -0.0899154543876648, -0.10215707868337631, -0.2323201596736908, -0.09915574640035629, 0.012598183006048203, 0.13644108176231384, -0.008870209567248821, 0.088738813996315, -0.1443847119808197, 0.11333418637514114, -0.07484068721532822, 0.007527108304202557, 0.09322088956832886, -0.04379095137119293, -0.11216345429420471, 0.18829691410064697, -0.025030795484781265, -0.10961948335170746, 0.19031351804733276, -0.027289625257253647, 0.2534421682357788, -0.08141248673200607, 0.14440211653709412, 0.1483764797449112, -0.022305302321910858, -0.04813099652528763, -0.061051346361637115, 0.2079043984413147, -0.21269378066062927, 0.1696094572544098, 0.09477456659078598, -0.10561162233352661, 0.042759969830513, 0.05991341918706894, -0.1161578893661499, -0.031045973300933838, 0.06571018695831299, -0.08852298557758331, 0.0051950495690107346, 0.10459479689598083, 0.07084715366363525, -1.310729539223019e-32, -0.0636725202202797, 0.11347690224647522, -0.041368573904037476, -0.02626306563615799, -0.04647211730480194, 0.15323078632354736, 0.190153568983078, -0.10306534171104431, 0.18295302987098694, -0.182649165391922, 0.06923943758010864, 0.018094751983880997, -0.09675860404968262, -0.07473649084568024, -0.15350335836410522, 0.11020601540803909, -0.17416474223136902, -0.2461492121219635, -0.07408986985683441, 0.08271975815296173, 0.15776070952415466, 0.14600570499897003, -0.13087666034698486, 0.12584641575813293, 0.05789691209793091, 0.030303366482257843, 0.12158050388097763, 0.04275287315249443, -0.023935455828905106, -0.021449686959385872, -0.16618862748146057, -0.004924957640469074, -0.2079356610774994, 0.02361159957945347, -0.11335603147745132, 0.005126960575580597, 0.09431026875972748, -0.11046566814184189, -0.10221828520298004, -0.07259073853492737, -0.007247773930430412, 0.048144709318876266, -0.0281527116894722, 0.02354591339826584, -0.0005824691615998745, 0.07492254674434662, 0.09829671680927277, -0.03671906143426895, 0.19117210805416107, 0.04093930125236511, -0.03995199874043465, 0.06545869261026382, -0.012048996984958649, 0.015290558338165283, -0.06689231842756271, -0.09620781987905502, 0.115043044090271, -0.020305689424276352, -0.1022869423031807, 0.09860878437757492, -0.038714125752449036, -0.013104645535349846, 0.14853769540786743, -0.03187981992959976, 0.08414837718009949, 0.011519072577357292, 0.0873657837510109, -0.012830602936446667, -0.042289480566978455, -0.04301568120718002, -0.13821622729301453, -0.11016836762428284, 0.026185302063822746, 0.005463615991175175, 0.11105349659919739, -0.0019620698876678944, -0.06805478781461716, -0.17279264330863953, -0.13297826051712036, 0.06360642611980438, -0.006695808842778206, -0.06996335834264755, -0.07426297664642334, 0.11215674877166748, 0.051076605916023254, 0.01702496036887169, 0.1087815910577774, -0.04249566048383713, 0.04460214078426361, 0.03789754956960678, -0.028748352080583572, -0.0026657795533537865, -0.07980437576770782, 0.17687803506851196, -0.020074281841516495, -1.008680641234605e-07, 0.131008118391037, -0.004043014720082283, -0.042705219238996506, -0.12575742602348328, -0.021343588829040527, -0.02324051782488823, -0.052191294729709625, 0.19505149126052856, 0.03451758995652199, -0.0025090817362070084, 0.05597367510199547, 0.2884002923965454, -0.16903135180473328, 0.02999858371913433, 0.0450424887239933, 0.027687620371580124, -0.14464309811592102, -0.040491193532943726, -0.051147669553756714, -0.0895678699016571, -0.1279708445072174, 0.06711870431900024, -0.07800769805908203, -0.022780291736125946, 0.05046198517084122, -0.09438580274581909, 0.13707955181598663, 0.0797966718673706, 0.08122743666172028, -0.07305146753787994, 0.10572884231805801, -0.01781638339161873, 0.017444375902414322, 0.060602448880672455, -0.1305467188358307, -0.17173108458518982, 0.018756281584501266, 0.1592557430267334, 0.030543100088834763, 0.2485591471195221, -0.02098829112946987, 0.04364027455449104, -0.026445183902978897, -0.01297365128993988, -0.14252683520317078, -0.0514536090195179, -0.1674635261297226, 0.08060964941978455, 0.03532058000564575, -0.11029668152332306, -0.1250162124633789, -0.026444151997566223, -0.007993955165147781, -0.062416836619377136, 0.01398841105401516, 0.1655806601047516, -0.08221928030252457, 0.0030154925771057606, -0.03134363144636154, -0.10701712965965271, -0.03212207928299904, -0.18756766617298126, 0.022726887837052345, 0.03183859586715698], "changes": {"1wk": -15.217394121202505}}, {"text": "4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path 4D Molecular Therapeutics, Inc. Fri, Jan 10, 2025, 4:00 PM 8 min read In This Article: FDMT +5.89% 4D Molecular Therapeutics, Inc. Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level 3E10 vg/eye demonstrated strong signals of clinical activity with sustained gain of BCVA of +8.4 letters and reduction of CST of -194 \u00b5m from baseline through Week 32 3E10 vg/eye achieved an 86% reduction in injection burden vs. projected on-label aflibercept 2mg Q8W and dose response with 61% reduction vs. 1E10 vg/eye, with 0.6 mean supplemental injections per patient through Week 32 FDA aligned with proposed single Phase 3 clinical trial being acceptable for the basis of a BLA submission for 4D-150 in DME, based on review of data from SPECTRA and PRISM (wet AMD) clinical trials to date and planned global Phase 3 clinical development program for wet AMD EMERYVILLE, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics\u00a0(Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced positive topline interim data from Part 1 of the SPECTRA clinical trial evaluating 4D-150 in diabetic macular edema (DME) and alignment with the U.S. Food and Drug Administration (FDA) on registrational pathway for 4D-150 in DME. \u201cThe promising initial safety and clinical activity data of 4D-150 in DME patients, together with the promising results in wet age-related macular degeneration (wet AMD), reinforces the potential applicability of 4D-150 across multiple VEGF-driven retinal diseases,\u201d said Carlos Quezada-Ruiz, M.D., FASRS, SVP, Therapeutic Area Head, Ophthalmology. \u201c4D-150 represents a potentially transformative new therapeutic option for the approximately one million DME patients in the U.S. alone. 4D-150 has the potential to set a new backbone therapy providing multi-year sustained VEGF inhibition in the retina with a single, safe, intravitreal injection. If approved, 4D-150 could significantly reduce the need for frequent bolus injections and address the current real-world challenge of patient adherence to therapy, thereby leading to better disease management and vision outcomes.\u201d Clinical Trial Design & Interim Data from 4D-150 SPECTRA Part 1 Clinical Trial (Data Cutoff of December 13, 2024): Objectives : Evaluate safety and tolerability and identify dose level for further evaluation Utilized stringent supplemental aflibercept criteria and enrolled patients with high central subfield thickness (CST) to maximize patient safety and assess initial clinical activity Study Population : 22 patients enrolled across 3 dose levels: 3E10 vg/eye (n=9), 1E10 vg/eye (n=12), 5E9 vg/eye (n=1); 1 patient in 1E10 vg/eye arm terminated the study due to death unrelated to 4D-150, prior to completion of a post-baseline assessment Safety (n=21) : 4D-150 was well tolerated with no intraocular inflammation at any timepoint All patients completed the 16-week topical corticosteroid taper on schedule and remained completely off steroids No hypotony, endophthalmitis, vasculitis, choroidal effusions or retinal artery occlusions Efficacy Results Through 32 Weeks : 3E10 vg/eye arm: Sustained gain of best corrected visual acuity (BCVA) of +8.4 letters Sustained reduction of CST, as measured by optical coherence tomography (OCT), of -194 \u00b5m Supplemental injections : Post-aflibercept loading doses (3), 3E10 vg/eye achieved substantially fewer supplemental injections compared to 1E10 vg/eye and projected on-label aflibercept 2mg Q8W: Mean injections per patient: 3E10 vg/eye: 0.6, 1E10 vg/eye: 1.4, projected on-label aflibercept 2mg Q8W: 4.0 3E10 vg/eye demonstrated a reduction of 61% vs. 1E10 vg/eye 3E10 vg/eye demonstrated a reduction of 86% vs. projected on-label aflibercept 2mg Q8W 0-1 injections: 8 of 9 overall (3E10 vg/eye) vs. 5 of 10 (1E10 vg/eye, 1 patient missed Week 24-32 visits) Injection-free: 5 of 9 overall (3E10 vg/eye) vs. 2 of 10 overall (1E10 vg/eye) 5 of 8 in patients treated per protocol (3E10 vg/eye) Results to be presented in a corporate webcast on February 10, 2025 52-week interim data update expected at a scientific conference in mid-2025 Data slides can be found on the \u201cInvestors\u201d section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/ Story Continues 4D-150 DME Phase 3 Regulatory Update & Next Steps 3E10 vg/eye has been selected as the Phase 3 dose Based on data generated to date for 4D-150 in both the SPECTRA and PRISM clinical trials, FDA is aligned that a single Phase 3 clinical trial, combined with data from the two planned Phase 3 clinical trials in the 4FRONT wet AMD program, would be acceptable as the basis of a BLA submission for 4D-150 in DME Per FDA feedback, the Company may proceed to Phase 3 (SPECTRA Part 2 no longer needed) and is aligned with key design elements of a Phase 3 clinical trial with approximately 300-400 patients total with a primary endpoint of BCVA noninferiority vs. on-label aflibercept 2mg (5 loading doses and Q8W), and revised supplemental injection criteria (less stringent compared to Part 1 SPECTRA, in line with prior successful Phase 3 DME clinical trials) Next steps for DME development to be presented in a corporate webcast on February 10, 2025 \u201cThe highly differentiated tolerability and promising clinical activity profile to date for 4D-150, and supportive feedback we received from the FDA in both wet AMD and DME, is a testament to 4D-150\u2019s differentiated product design based on our proprietary R100 vector and our strong team, including our global Ophthalmology Advisory Board,\u201d said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. \u201cThe alignment with the FDA on the design and path forward for a single Phase 3 trial in DME is a positive step forward in our ability to realize 4D-150\u2019s potential as a pipeline-in-a-product, which may unlock DME as a second large market indication shortly after wet AMD.\" About 4D-150 4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) from the retina with a single, safe, intravitreal injection. 4D-150 utilizes our customized and evolved intravitreal vector, R100, which was invented at 4DMT through our proprietary Therapeutic Vector Evolution platform. 4D-150 is being developed for wet AMD and DME which both affect millions of patients globally, with the goal of freeing patients from burdensome injections while preserving vision. About DME DME, or diabetic macular edema, is a complication of diabetic retinopathy and is a highly prevalent disease with significant unmet medical need and poor treatment adherence. It is estimated that there are approximately one million individuals with DME in the U.S. according to published data. DME is characterized by inflammation swelling in the macula due to leakage from blood vessels, which can lead to vision loss. DME is typically treated with intravitreal anti-VEGF agents administered approximately every 4-12 weeks, although patient compliance with therapy is poor and results in high unmet medical need. About 4DMT 4DMT is a late-stage biotechnology company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT\u2019s proprietary invention platform, Therapeutic Vector Evolution, combines the power of directed evolution with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our lead program 4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) targeted to the retina with a single, safe, intravitreal injection. Our second core program is 4D-710, which is the first known genetic medicine to demonstrate, in the lungs of people with cystic fibrosis (CF), successful delivery and expression of the CFTR transgene and initial clinical activity signals after aerosol delivery of a gene therapy. 4D Molecular Therapeutics\u2122, 4DMT\u2122, Therapeutic Vector Evolution\u2122, and the 4DMT logo are trademarks of 4DMT. All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the FDA or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied. Learn more at www.4DMT.com and follow us on LinkedIn . Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the therapeutic potential, and clinical benefits and market potential of 4DMT\u2019s product candidates, as well as the plans, announcements, and related timing for the clinical development of and regulatory interactions regarding 4D-150. The words \"may,\" \u201cmight,\u201d \"will,\" \"could,\" \"would,\" \"should,\" \"expect,\" \"plan,\" \"anticipate,\" \"intend,\" \"believe,\" \u201cexpect,\u201d \"estimate,\" \u201cseek,\u201d \"predict,\" \u201cfuture,\u201d \"project,\" \"potential,\" \"continue,\" \"target\" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including risks and uncertainties that are described in greater detail in the section entitled \"Risk Factors\" in 4D Molecular Therapeutics\u2019 most recent Quarterly Report on Form 10-Q filed on November 13, 2024 as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent 4D Molecular Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. 4D Molecular Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Contacts: Media: Katherine Smith Inizio Evoke Comms Media@4DMT.com Investors: Julian Pei Head of Investor Relations and Corporate Finance Investor.Relations@4DMT.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "FDMT", "date": "2025-01-10T13:00:00+00:00", "sentiment": {"score": 0.9197276681661606, "confidence": 0.9301174283027649, "probabilities": {"positive": 0.9301174283027649, "negative": 0.010389760136604309, "neutral": 0.05949276313185692}}, "embedding": [-0.043674688786268234, -0.10597588121891022, 0.07590024918317795, -0.09056603908538818, -0.06017417833209038, -0.1246756911277771, -0.036047499626874924, 0.2136596441268921, -0.005318262614309788, 0.16451776027679443, -0.10593314468860626, -0.04441611096262932, -0.0020622219890356064, 0.09176376461982727, -0.04455427825450897, 0.1334088295698166, -0.0700729563832283, 0.023610739037394524, -0.14785754680633545, 0.04288967326283455, 0.057930365204811096, 0.015061192214488983, 0.012307830154895782, 0.006895723752677441, -0.16856783628463745, 0.013543274253606796, 0.019909169524908066, -0.08637593686580658, -0.1052914559841156, -0.13607344031333923, 0.04002389311790466, 0.18736699223518372, -0.023347193375229836, 0.001997108571231365, -0.0890297144651413, -0.07605285942554474, -0.12272876501083374, -0.11768035590648651, -0.22163966298103333, -0.034792833030223846, -0.032545123249292374, 0.10088492929935455, -0.1465497761964798, 0.1291472315788269, 0.15867048501968384, -0.14572644233703613, -0.07168585062026978, -0.003917692694813013, 0.006713682319968939, 0.18608438968658447, -0.011726364493370056, 0.004287845455110073, -0.07534323632717133, 0.13848662376403809, -0.003969266079366207, -0.02696327492594719, -0.19210287928581238, -0.052567481994628906, 0.14788571000099182, 0.10467750579118729, 0.08459743857383728, -0.06646758317947388, 0.02837514877319336, -0.06450916826725006, 0.08782955259084702, 0.0867348164319992, 0.055243879556655884, -0.1276398003101349, -0.08207660168409348, -0.18856674432754517, -0.013129666447639465, -0.03092801198363304, 0.07106539607048035, 0.03470602631568909, -0.06651255488395691, 0.06922753155231476, 0.14698246121406555, 0.00859557744115591, 0.0410805344581604, -0.10353579372167587, 0.15946993231773376, 0.18175816535949707, 0.14744925498962402, -0.11516821384429932, 0.12756632268428802, 0.06644078344106674, -0.07909269630908966, 0.06681826710700989, 0.009401005692780018, 0.07742460817098618, 0.034881167113780975, -0.0009085303172469139, -0.11318247765302658, 0.09758074581623077, -0.045213133096694946, 0.0012191152200102806, 0.0043975492008030415, -0.09454300999641418, 0.03466256707906723, 0.006183817982673645, 0.008315902203321457, 0.024237576872110367, -0.1612870693206787, -0.007571724243462086, -0.014916581101715565, -0.09644673764705658, 0.24431443214416504, 0.0055252183228731155, -0.09817536175251007, -0.05291442945599556, 0.0991385281085968, 0.1166747510433197, 0.01985849440097809, 0.10799300670623779, -0.13459254801273346, 0.1596812903881073, -0.022497937083244324, -0.015239143744111061, 0.26433444023132324, -0.12164464592933655, 0.031860459595918655, 0.003971845842897892, 0.12705905735492706, -0.1090981513261795, 0.10897661745548248, 0.07402507215738297, -0.012460485100746155, 9.015818326880289e-33, 0.03618638962507248, 0.007635260000824928, 0.013512681238353252, 0.058680422604084015, 0.014273897744715214, -0.11702955514192581, 0.07472166419029236, 0.04660218581557274, -0.24904599785804749, -0.058987803757190704, -0.22299200296401978, -0.040634553879499435, 0.024950306862592697, 0.1932770013809204, -0.06328767538070679, -0.114139623939991, 0.053509633988142014, 0.08084078878164291, -0.016736576333642006, -0.1310623735189438, -0.01820659264922142, 0.11646081507205963, -0.04978591948747635, 0.034047141671180725, -0.02803325094282627, 0.1769046187400818, -0.039847783744335175, 0.13510531187057495, 0.11698131263256073, 0.06440979242324829, -0.2273288369178772, 0.04684029519557953, 0.05373632162809372, -0.14044632017612457, 0.03275274857878685, -0.05226559191942215, 0.04311516880989075, -0.11205706000328064, 0.004748542793095112, 0.10090256482362747, -0.039653219282627106, 0.0666300505399704, -0.09131677448749542, -0.1808217465877533, 0.06111108884215355, -0.011799745261669159, -0.09540659189224243, -0.005113003775477409, -0.08800049126148224, 0.08400215208530426, -0.07984331995248795, -0.034926705062389374, 0.07514211535453796, -0.0741489827632904, -0.12202081084251404, 0.014431011863052845, -0.2042115330696106, -0.04013727605342865, 0.11286573857069016, 0.09061740338802338, -0.01046297699213028, 0.011000473983585835, -0.1160389631986618, 0.12915465235710144, 0.003340916708111763, -0.010257285088300705, 0.07191286981105804, -0.03127080202102661, -0.18382513523101807, 0.017619682475924492, 0.08496764302253723, -0.09369126707315445, 0.15156583487987518, -0.05204179510474205, 0.22853365540504456, 0.014741924591362476, 0.12001821398735046, 0.21211020648479462, -0.034348972141742706, -0.007661668583750725, -0.011483163572847843, 0.2095402181148529, -0.20717541873455048, 0.09163301438093185, 0.03883383423089981, -0.061090853065252304, 0.11191721260547638, 0.03246861323714256, -0.09876801818609238, -0.08889627456665039, 0.11835137009620667, -0.04189498722553253, -0.04896286875009537, -0.05763896554708481, 0.023876391351222992, -1.0009141910051831e-32, -0.07598049938678741, 0.08997941017150879, -0.01307276077568531, -0.05353113263845444, -0.08593904972076416, 0.21655863523483276, 0.25035563111305237, -0.03244355320930481, 0.24041618406772614, -0.23420220613479614, 0.11524122953414917, 0.031457316130399704, -0.12015259265899658, -0.10064148902893066, -0.1612781286239624, 0.10846542567014694, -0.24449367821216583, -0.1306455433368683, -0.1457216888666153, 0.1338045746088028, 0.0936356782913208, 0.11295053362846375, -0.06700772792100906, -0.00023066531866788864, 0.11469340324401855, 0.024431169033050537, 0.18238547444343567, 0.05090311914682388, -0.03395429253578186, 0.04041140899062157, -0.06815989315509796, 0.06557875126600266, -0.1870119571685791, 0.03431713208556175, -0.09084074199199677, -0.026439670473337173, 0.044202424585819244, -0.0814700648188591, -0.13751208782196045, -0.0012076282873749733, -0.03938121348619461, 0.13758650422096252, -0.0337863489985466, -0.012506620958447456, 0.0038987062871456146, 0.0956803411245346, 0.05029894411563873, -0.019549451768398285, 0.1796553134918213, 0.06162207946181297, -0.01072029396891594, 0.030241219326853752, 0.050659604370594025, -0.0051388852298259735, -0.08720581978559494, -0.15651074051856995, 0.08624880015850067, 0.002955732401460409, -0.09275387227535248, 0.06904710084199905, -0.023044083267450333, -0.10016568005084991, 0.1830902099609375, -0.06981424242258072, 0.0758994072675705, 0.10098563134670258, 0.059172991663217545, -0.013056128285825253, 0.11593218147754669, -0.09314790368080139, -0.07825518399477005, -0.1323259025812149, -0.07905048877000809, -0.040449026972055435, 0.04028300195932388, 0.01838470622897148, -0.018279515206813812, -0.11593011766672134, -0.12986567616462708, 0.08658099919557571, 0.03712351620197296, -0.06146284565329552, -0.09168024361133575, 0.07773679494857788, -0.014719197526574135, 0.005384592805057764, 0.1585821807384491, -0.006628116592764854, 0.06729857623577118, 0.06604144722223282, -0.14016267657279968, -0.0447528138756752, -0.1433628797531128, 0.1544952541589737, -0.012572580948472023, -1.0095960334410847e-07, 0.1643078476190567, -0.007359195034950972, -0.02609298750758171, -0.07432551681995392, -0.011716671288013458, -0.02997526153922081, -0.0919724777340889, 0.117531418800354, -0.006944255903363228, -0.019943751394748688, 0.055480409413576126, 0.20819775760173798, -0.1639525592327118, 0.007897275499999523, 0.02689930982887745, 0.04526052623987198, -0.09992332011461258, -0.05979057028889656, -0.04317232966423035, 0.03000006265938282, -0.08194802701473236, 0.04983147978782654, 0.04465179890394211, -0.08547207713127136, 0.06653667986392975, 0.021380482241511345, 0.03234994411468506, 0.040550194680690765, 0.0650317370891571, -0.13563242554664612, 0.12845629453659058, 0.005525970831513405, 0.024618178606033325, 0.007242606952786446, -0.14134743809700012, -0.15258082747459412, -0.010463312268257141, 0.1920613944530487, 0.023907184600830078, 0.1976766288280487, -0.0994325578212738, -0.05302759259939194, 0.007991828955709934, 0.010136213153600693, -0.13041216135025024, -0.03246993571519852, -0.1124873012304306, 0.016580132767558098, 0.011378265917301178, -0.07797083258628845, -0.1478504240512848, -0.08802806586027145, -0.0034736739471554756, -0.11829416453838348, -0.13627628982067108, 0.09172746539115906, -0.010308411903679371, -0.016406144946813583, -0.07397475093603134, -0.1620473861694336, 0.004180006682872772, -0.09460030496120453, -0.01234058104455471, 0.027275776490569115], "changes": {"1wk": -15.217394121202505}}, {"text": "4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates Zacks Equity Research Thu, Nov 14, 2024, 1:20 AM 3 min read In This Article: FDMT +5.89% 4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.24 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -17.91%. A quarter ago, it was expected that this company would post a loss of $0.72 per share when it actually produced a loss of $0.63, delivering a surprise of 12.50%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. 4D Molecular Therapeutics , which belongs to the Zacks Medical - Drugs industry, posted zero revenues for the quarter ended September 2024, missing the Zacks Consensus Estimate by 99.76%. This compares to year-ago revenues of $20.2 million. The company has not been able to beat consensus revenue estimates over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. 4D Molecular Therapeutics shares have lost about 61.2% since the beginning of the year versus the S&P 500's gain of 25.5%. What's Next for 4D Molecular Therapeutics? While 4D Molecular Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for 4D Molecular Therapeutics: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.70 on $3.7 million in revenues for the coming quarter and -$2.74 on $5.11 million in revenues for the current fiscal year. Story Continues Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 25% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Cosmos Health Inc. (COSM), has yet to report results for the quarter ended September 2024. This company is expected to post quarterly loss of $0.11 per share in its upcoming report, which represents a year-over-year change of -22.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Cosmos Health Inc.'s revenues are expected to be $14 million, up 9.2% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report 4D Molecular Therapeutics, Inc. (FDMT) : Free Stock Analysis Report Cosmos Health Inc. (COSM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "FDMT", "date": "2024-11-13T22:20:07+00:00", "sentiment": {"score": -0.8481951877474785, "confidence": 0.8809125423431396, "probabilities": {"positive": 0.03271735459566116, "negative": 0.8809125423431396, "neutral": 0.08637013286352158}}, "embedding": [-0.05756691098213196, -0.014956683851778507, 0.031080663204193115, -0.0018867584876716137, -0.005155928432941437, -0.029955284669995308, -0.07153777778148651, 0.2395731508731842, 0.28172439336776733, 0.1539495587348938, -0.12830151617527008, 0.1219867393374443, -0.04764797165989876, 0.01425999216735363, -0.10575971007347107, -0.012509962543845177, -0.02213834784924984, 0.02341214381158352, -0.13879252970218658, 0.0326705127954483, -0.09693542867898941, 0.01917954534292221, 0.2050553411245346, 0.056116074323654175, 0.06351736932992935, 0.002802439033985138, -0.07300589978694916, -0.0160985067486763, -0.1358741819858551, -0.07670228183269501, -0.03166766092181206, 0.15508806705474854, 0.051359690725803375, -0.09385707974433899, -0.0519595630466938, -0.06511874496936798, -0.04490121081471443, 0.05950719490647316, 0.06043136119842529, 0.0028068451210856438, -0.03994274139404297, 0.03410288691520691, -0.1520816832780838, 0.07517552375793457, -0.085274837911129, -0.184864342212677, -0.0690733939409256, -0.016792187467217445, 0.05010396987199783, 0.1269960254430771, -0.07680356502532959, -0.04645324870944023, 0.018198523670434952, 0.0669904500246048, -0.08560629934072495, 0.04604484885931015, -0.15919971466064453, -0.04887767508625984, 0.04259422421455383, 0.12167539447546005, 0.12804944813251495, 0.03754371404647827, -0.012443061918020248, 0.049615636467933655, 0.245286226272583, 0.058632977306842804, 0.05966249853372574, 0.08587957918643951, -0.13349153101444244, 0.018119724467396736, 0.12147033214569092, 0.022070879116654396, -0.04098944365978241, -0.011851352639496326, -0.10725320130586624, 0.06093015521764755, 0.09548865258693695, 0.12076921761035919, 0.0901341512799263, -0.024472618475556374, 0.10648036003112793, -0.0010507464176043868, 0.02579590305685997, -0.10125970840454102, 0.00919928029179573, 0.03087542951107025, 0.12100169062614441, 0.11498032510280609, 0.02269873395562172, 0.01657581329345703, -0.03157271444797516, -0.016508515924215317, -0.05559023469686508, -0.04972107335925102, -0.029471762478351593, 0.06076284125447273, -0.058186762034893036, -0.13214287161827087, 0.059149667620658875, 0.07586020231246948, 0.0946786105632782, 0.09482090175151825, -0.11296626925468445, -0.12693241238594055, 0.027275601401925087, -0.10397040843963623, 0.09119878709316254, 0.011123232543468475, -0.02818473055958748, 0.06263741850852966, -0.05971449613571167, 0.10771109908819199, -0.10270361602306366, -0.0001677209511399269, -0.0994262546300888, 0.09196837246417999, -0.029187168926000595, 0.08949194848537445, 0.07792563736438751, 0.09941563755273819, -0.0441165454685688, 0.06415984034538269, 0.07031376659870148, -0.0217302143573761, 0.008392013609409332, 0.021041899919509888, -0.1676013469696045, 8.664078091019613e-33, 0.13127592206001282, 0.08543534576892853, 0.07214846462011337, -0.040016017854213715, 0.008669521659612656, -0.01613357663154602, 0.059977900236845016, -0.06548040360212326, -0.1165802925825119, -0.09920243918895721, -0.14649853110313416, -0.00751105509698391, 0.009441949427127838, -0.0854867547750473, -0.01685720682144165, -0.12531769275665283, -0.005984761752188206, 0.06954214721918106, 0.08186174929141998, -0.07624081522226334, 0.002333416137844324, 0.041438810527324677, -0.028844065964221954, 0.08092044293880463, 0.006555942818522453, 0.054250702261924744, -0.13552109897136688, 0.11708629876375198, -0.07173565030097961, 0.047689855098724365, -0.18489022552967072, 0.03549060970544815, 0.04688820615410805, -0.2033812254667282, -0.012453582137823105, -0.08504690229892731, -0.09221726655960083, -0.05101756006479263, 0.15129172801971436, 0.032945044338703156, -0.1052679717540741, 0.03869473934173584, -0.15804043412208557, -0.2654271721839905, -0.05654337257146835, 0.06456257402896881, -0.0663815438747406, -0.026842378079891205, -0.11083956062793732, 0.06507375091314316, -0.03688214719295502, 0.0626361221075058, 0.015296392142772675, 0.00023789890110492706, -0.06859096884727478, -0.05086521804332733, -0.12078096717596054, -0.2391529679298401, 0.03055836632847786, 0.18519893288612366, 0.11597010493278503, 0.2726869583129883, -0.02774650789797306, 0.01967158354818821, -0.23777830600738525, 0.11802448332309723, 0.05115503445267677, 0.006259683519601822, -0.09812033921480179, 0.24434012174606323, -0.01620163768529892, -0.056545689702034, 0.1256282925605774, -0.1419057697057724, 0.3084641993045807, -0.09346256405115128, 0.01593586802482605, -0.0843425989151001, 0.08531320840120316, 0.04152332991361618, 0.05481434985995293, -0.03517523780465126, -0.060617320239543915, 0.02620471641421318, 0.005297556519508362, -0.1016012579202652, 0.025994841009378433, 0.04088778421282768, 0.026585664600133896, -0.0010312236845493317, 0.06080683320760727, -0.22863152623176575, -0.11348344385623932, 0.10585004836320877, 0.05030995234847069, -8.411293908347034e-33, -0.0767880231142044, 0.12716591358184814, 0.010914367623627186, -0.04067648574709892, -0.06922633945941925, 0.012377223931252956, 0.09783327579498291, 0.11139075458049774, 0.08314922451972961, -0.0199638269841671, 0.07291250675916672, 0.056885648518800735, -0.18670350313186646, 0.06798238307237625, -0.08740706741809845, 0.054298512637615204, 0.05697162449359894, -0.23480278253555298, 0.06884253025054932, -0.003188707400113344, 0.05314204469323158, 0.16698914766311646, -0.12452538311481476, 0.16103896498680115, 0.06447719037532806, 0.09195864200592041, 0.05612154304981232, 0.14308303594589233, 0.017131933942437172, -0.07505668699741364, 0.011332797817885876, -0.04765602946281433, -0.19250059127807617, 0.10293260961771011, -0.016890794038772583, -0.0460725873708725, 0.047891415655612946, -0.07995574176311493, -0.05315251648426056, -0.08383701741695404, 0.1406799852848053, 0.0563054084777832, 0.022964468225836754, 0.057763002812862396, 0.07668673247098923, 0.01713581569492817, 0.03695123270153999, 0.023402327671647072, 0.2360488772392273, 0.06591745465993881, 0.0027165263891220093, 0.02398858405649662, -0.045588720589876175, 0.0931178480386734, -0.14115017652511597, -0.06812843680381775, -0.03386173024773598, 0.016000868752598763, -0.15358537435531616, 0.09711859375238419, -0.0668400377035141, 0.013302446343004704, 0.05556777864694595, 0.06889330595731735, 0.009910492226481438, -0.027401763945817947, 0.05594627186655998, 0.004802130162715912, 0.07142893224954605, -0.08854290843009949, 0.010768149048089981, -0.07037520408630371, 0.09452878683805466, -0.09726187586784363, 0.07001222670078278, 0.23211178183555603, -0.04271083325147629, -0.19977185130119324, -0.1287347674369812, 0.052773915231227875, 0.09286653995513916, 0.022736236453056335, 0.013565512374043465, -0.015327861532568932, -0.128305584192276, 0.09651204943656921, 0.08675834536552429, -0.022781213745474815, -0.06904329359531403, -0.0498901903629303, -0.020444665104150772, -0.13295823335647583, -0.10975082963705063, 0.06742905080318451, 0.121892049908638, -9.992193383823178e-08, 0.10481147468090057, -0.06729476153850555, 0.05224211886525154, -0.06164693832397461, 0.08839284628629684, -0.020410485565662384, 0.043261218816041946, 0.0697915256023407, 0.10031253099441528, 0.11092251539230347, 0.007839489728212357, 0.11054172366857529, -0.2613741457462311, -0.013436820358037949, -0.06807301193475723, 0.023098740726709366, -0.18518602848052979, -0.02587447687983513, -0.025743864476680756, -0.1698770821094513, -0.10944902151823044, 0.10927332937717438, 0.051852837204933167, -0.10874225199222565, 0.018789807334542274, -0.036583613604307175, -0.023784009739756584, -0.07973939180374146, -0.003743935376405716, -0.0207639392465353, 0.15703091025352478, -0.03112472966313362, 0.02505618706345558, 0.09541751444339752, -0.0875396803021431, -0.1884833425283432, 0.07175474613904953, 0.09020828455686569, 0.0044923522509634495, 0.14025434851646423, -0.08904550224542618, 0.05056457966566086, -0.01564040780067444, 0.031483594328165054, -0.10721603035926819, -0.09811097383499146, -0.1063634604215622, 0.04048344865441322, 0.0371142141520977, -0.27211710810661316, 0.10276859253644943, -0.05624864250421524, -0.044954586774110794, -0.01471279188990593, 0.025983504951000214, 0.07257161289453506, -0.19300079345703125, -0.007205758709460497, -0.20291078090667725, -0.15014168620109558, 0.02816302515566349, -0.280972421169281, 0.059338413178920746, 0.1275424063205719], "changes": {"1wk": 9.079115509750052, "1mo": -15.693904437875789}}, {"text": "4D Molecular Therapeutics, Inc. (FDMT): An Oversold Healthcare Stock to Invest In Now Laiba Immad Tue, Nov 26, 2024, 2:51 PM 6 min read In This Article: FDMT +5.89% We recently compiled a list of the 10 Oversold Healthcare Stocks To Invest In . In this article, we are going to take a look at where 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) stands against the other oversold healthcare stocks. The Promising Outlook for Healthcare Investments in 2024 Investing in healthcare stocks during lean economic times is generally regarded as defensive. This is because people typically do not cut back on their use of prescription medications or other essential healthcare services, even during difficult financial times. According to the Centers for Medicare and Medicaid Services (CMS), national healthcare spending is projected to reach an estimated $4.8 trillion in 2023 and grow at an annual rate of 5.6% between 2027 and 2032. In the US, the healthcare sector is flourishing. According to a recent estimate, the country's healthcare spending increased by 7.5% in 2023, above the nominal GDP growth rate for the same year. A record 93.1% of Americans now have health insurance, which helped fuel last year's sharp increase in healthcare spending. The United States' national healthcare spending is expected to increase at an average rate of 5.6% between 2023 and 2032, above the 4.3% growth predicted for GDP. Additionally, the industry is growing quickly on a global scale. According to recent McKinsey projections, healthcare profits would increase at a compound annual growth rate (CAGR) of 7% from $583 billion in 2022 to over $800 billion by 2027. Although labor shortages and rising inflation rates continued to put pressure on the business in 2023, a good risk-reward climate in the sector is expected to make 2024 a year of recovery. According to the American investment firm, the events of 2023 have produced an alluring opportunity for investors to engage in the healthcare industry. Investments in AI within the healthcare sector have grown rapidly, outpacing the tech industry, with $2.8 billion invested in AI healthcare corporations in 2024, and over $11 billion expected by the end of the year. According to a Silicon Valley Bank report, one-quarter of healthcare spending now goes to AI-driven companies. Deloitte's 2024 Global Health Care Sector Outlook highlights high investor confidence, with $31.5 billion in private equity funding between 2019 and 2022. AI is expected to save $360 billion in U.S. healthcare over the next five years by improving patient care, diagnosis, treatment, and medical administration. Optimism in the healthcare industry is growing as 2024 goes on. Financial experts anticipate better earnings this year despite 2023's poor performance. The healthcare industry has a \"favorable risk-reward environment,\" according to BlackRock's 2024 prediction, which also notes that investors now have an appealing starting point because of last year's poor performance. In view of this, we will take a look at oversold stocks from the healthcare sector. Story Continues Our Methodology For our methodology, we used a stock screener and selected healthcare stocks that had an RSI below 30, mid-market cap, and high institutional ownership. Then we ranked the stocks based on their total number of hedge fund holders as of Insider Monkey\u2019s database of Q3 2024. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points ( see more details here ). An ophthalmologist performing an eye examination on a patient with the latest medical equipment. 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) Number of Hedge Fund Holders: 24 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is a clinical-stage biopharmaceutical company that specializes in gene therapy products for serious unmet medical conditions. The company develops customized gene delivery vehicles, or vectors, to transport therapeutic genetic material into specific cells. Its main focus areas include treatments for ophthalmology, pulmonology, and cardiology. The company's lead candidate, 4D-150 for wet AMD, has shown promising results in Phase 1/2 trials. Interim data demonstrated a robust and durable reduction in anti-VEGF injection treatment burden, with an overall reduction of 83% in the severe population As of September 30, 2024, 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) reported $551 million in cash, cash equivalents, and marketable securities, which is expected to fund planned operations at least into the first half of 2027. This strong cash position provides a significant runway for the company to advance its clinical programs. The company's revenue for Q3 2024 was $3,000, a substantial decrease from $20.2 million in Q3 2023. This decline is likely due to the completion of certain collaboration agreements or milestone payments in the previous year. Research and development expenses increased to $38.5 million in Q3 2024 from $25.1 million in Q3 2023, reflecting the progression of clinical trials, particularly for 4D-150 in wet AMD and DME. 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has several anticipated milestones in early 2025 that could act as key catalysts for its stock. These include the release of 52-week interim data from the Phase 2b cohort of the PRISM clinical trial for 4D-150 in wet AMD in February 2025 and the initiation of the 4FRONT-1 Phase 3 clinical trial for the same condition in Q1 2025. Additionally, interim data updates from the SPECTRA clinical trial program for 4D-150 in diabetic macular edema (DME) are expected in early January 2025, alongside the planned Phase 1 enrollment for 4D-175 in geographic atrophy, also in Q1 2025. As tracked by the Insider Monkey database, 24 hedge fund holders held shares in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) in Q3 2024, with Biotechnology Value Fund / BVF Inc being the largest stakeholder with shares worth roughly $80 million. Street analysts hold a consensus Strong Buy rating on the stock. Overall FDMT ranks 10th on our list of the oversold healthcare stocks to invest in. While we acknowledge the potential of FDMT as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than FDMT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock . READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock Disclosure: None. This article is originally published at Insider Monkey . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "FDMT", "date": "2024-11-26T11:51:57+00:00", "sentiment": {"score": 0.8901690561324358, "confidence": 0.9134700894355774, "probabilities": {"positive": 0.9134700894355774, "negative": 0.023301033303141594, "neutral": 0.06322881579399109}}, "embedding": [0.006608203984797001, -0.10928211361169815, -0.02673768252134323, -0.061093468219041824, 0.026754330843687057, 0.07032303512096405, -0.00640942482277751, 0.15255269408226013, 0.11600819230079651, 0.1347087323665619, -0.1860690712928772, 0.2164333164691925, -0.06829702109098434, -0.053826216608285904, -0.07654176652431488, 0.010787548497319221, -0.035549428313970566, -0.047029972076416016, -0.10824153572320938, 0.19471700489521027, -0.04324387386441231, 0.01526789553463459, 0.10419470071792603, -0.004590855911374092, -0.042360901832580566, -0.0324726402759552, 0.03671758994460106, -0.1531897485256195, -0.2191179245710373, 0.06667660921812057, 0.06566980481147766, 0.09542562812566757, 0.0849798321723938, 0.021344494074583054, -0.08234213292598724, 0.05841699615120888, -0.0146126514300704, 0.060053616762161255, 0.0031753862276673317, 0.028157012537121773, -0.010197996161878109, -0.07294123619794846, -0.059152670204639435, 0.08625505119562149, 0.10793799161911011, -0.09893348813056946, -0.05677538737654686, 0.055949967354536057, 0.1124897450208664, 0.11172784119844437, -0.141810804605484, -0.029608208686113358, 0.05565797910094261, 0.03840487077832222, -0.01542058028280735, -0.034170784056186676, -0.09131546318531036, -0.06562628597021103, -0.06355384737253189, 0.1281765252351761, 0.024413323029875755, -0.0005139955319464207, 0.17807918787002563, -0.0025220122188329697, 0.109778493642807, 0.10588240623474121, 0.04168473929166794, 0.01613410748541355, -0.15075919032096863, 0.0728415846824646, 0.013795265927910805, -0.10100214928388596, -0.0009847511537373066, -0.12722033262252808, 0.007128562778234482, 0.047163914889097214, 0.044240739196538925, 0.14265446364879608, 0.19114455580711365, -0.11597708612680435, 0.18661364912986755, 0.03646259009838104, 0.045520931482315063, -0.07599125802516937, -0.043676819652318954, 0.013265125453472137, -0.01724229007959366, -0.0030155587010085583, 0.059101805090904236, -0.016771165654063225, 0.012402104213833809, -0.06949394196271896, -0.08167549967765808, -0.0453028529882431, 0.06140303611755371, 0.05003415048122406, -0.0930367261171341, 0.02733134664595127, -0.04346955567598343, -0.028165634721517563, 0.0715368464589119, 0.06755918264389038, 0.02956906147301197, -0.04285120964050293, -0.07659386098384857, -0.10866101831197739, 0.09851308166980743, -0.009142694063484669, 0.066608726978302, 0.024763483554124832, -0.03947184234857559, 0.06541722267866135, 0.003115808591246605, 0.014535589143633842, -0.05194186419248581, 0.07453365623950958, 0.06579381227493286, -0.0919022411108017, 0.10587894916534424, 0.1573861688375473, 0.020427118986845016, 0.055456142872571945, -0.0777599960565567, -0.06253515928983688, -0.051505330950021744, -0.034978702664375305, -0.21976473927497864, 4.898712913288568e-33, 0.02665683813393116, 0.05584941804409027, 0.1264185607433319, -0.07892870903015137, -0.14678524434566498, 0.013006535358726978, 0.058884911239147186, -0.08739037811756134, -0.11400528252124786, -0.09266162663698196, -0.20256975293159485, 0.03442296013236046, -0.06038752198219299, 0.07779821753501892, 0.05668819323182106, -0.20393534004688263, -0.0559660866856575, 0.13666154444217682, 0.03198666125535965, -0.024932732805609703, -0.05734019726514816, -0.019819587469100952, -0.024775255471467972, 0.04053511470556259, 0.0753333568572998, 0.01708296313881874, -0.07241227477788925, -0.048137325793504715, 0.07811234146356583, 0.02609945647418499, -0.05173647776246071, 0.06617569923400879, -0.09198956191539764, -0.09641443192958832, -0.07571113854646683, -0.16291053593158722, -0.06580593436956406, 0.09569644927978516, -0.013018084689974785, 0.007249314337968826, -0.04766000062227249, 0.08766116946935654, -0.00731375627219677, -0.01584097556769848, 0.028106052428483963, 0.027228575199842453, 0.018810782581567764, -0.03653647005558014, -0.12149234861135483, -0.08170740306377411, -0.12977352738380432, 0.056315600872039795, -0.03427141159772873, -0.07090585678815842, 0.039721205830574036, -0.10800951719284058, -0.09833616018295288, -0.17257007956504822, -0.0470510870218277, 0.035434748977422714, 0.024692127481102943, -0.0020789187401533127, -0.03179274499416351, 0.020696144551038742, -0.12463700771331787, 0.16878581047058105, 0.009523183107376099, 0.08935263752937317, -0.03399968892335892, 0.22861844301223755, 0.11048364639282227, -0.03735765442252159, -0.025234604254364967, -0.050632551312446594, 0.08081012219190598, 0.041904330253601074, 0.012604703195393085, -0.08758776634931564, 0.03054702654480934, 0.07456469535827637, -0.026656487956643105, -0.008086686953902245, -0.04078671708703041, 0.0329366996884346, 0.04630355164408684, -0.009708946570754051, 0.045611537992954254, 0.046789832413196564, 0.012364733032882214, -0.19165021181106567, -0.11152994632720947, -0.11084987223148346, 0.07075121998786926, 0.07473097741603851, -0.00529772974550724, -8.738881408718158e-33, -0.01278452854603529, 0.08094917237758636, 0.060402773320674896, -0.040401965379714966, 0.047503069043159485, -0.11288489401340485, 0.08013619482517242, 0.05488710477948189, 0.09677377343177795, -0.012265048921108246, 0.061600640416145325, 0.024958819150924683, 0.08113950490951538, 0.11205342411994934, -0.08573639392852783, -0.03521011024713516, -0.017962800338864326, -0.1490103006362915, 0.0542883425951004, -0.08288472890853882, 0.040386635810136795, 0.056969113647937775, 0.0016871746629476547, 0.1724683791399002, 0.008835687302052975, 0.1590782105922699, -0.12905333936214447, 0.1018541231751442, 0.1262420117855072, -0.11516748368740082, -0.14221510291099548, 0.05969793349504471, -0.12660793960094452, 0.07472135871648788, -0.06617671996355057, -0.004206283017992973, 0.03153711557388306, -0.11009741574525833, -0.004946025088429451, -0.10078652203083038, 0.24978479743003845, -0.04264495521783829, -0.1259138286113739, 0.017137560993433, 0.09900762885808945, -0.06177404150366783, 0.0019606631249189377, 0.07291355729103088, 0.1566421091556549, -0.05014162138104439, 0.012661222368478775, 0.040016788989305496, -0.02339419350028038, 0.06881542503833771, -0.17163392901420593, 0.09936253726482391, 0.05493950471282005, -0.04123261570930481, -0.14223411679267883, 0.00211807107552886, -0.09462077170610428, 0.06723953038454056, -0.0049157701432704926, -0.0509524792432785, -0.07248398661613464, -0.0781513899564743, 0.1057889461517334, -0.02590656839311123, 0.07624279707670212, -0.1618707776069641, 0.03199581056833267, -0.08602114021778107, -0.06362005323171616, -0.0466378778219223, -0.001940959133207798, 0.14344996213912964, 0.05647168681025505, -0.11770819872617722, -0.03822832927107811, 0.12395553290843964, 0.08678249269723892, -0.1644514501094818, -0.0036814382765442133, -0.13989418745040894, -0.14323927462100983, 0.028251832351088524, 0.092849962413311, -0.11778818070888519, -0.24462422728538513, 0.05926146358251572, -0.22846493124961853, -0.04410014674067497, -0.15070036053657532, 0.042336031794548035, -0.09764289855957031, -1.0042565179446683e-07, 0.16222883760929108, 0.037174440920352936, 0.10000328719615936, -0.09328977018594742, 0.08923438936471939, -0.18010202050209045, -0.05633646994829178, 0.12223244458436966, 0.0999121442437172, 0.13220641016960144, 0.06983095407485962, 0.1689777821302414, -0.022591926157474518, -0.006033448502421379, -0.08027281612157822, 0.12580865621566772, -0.2217109203338623, 0.0008137435652315617, -0.04117051512002945, -0.07823387533426285, 0.008804518729448318, 0.03887686878442764, -0.04004234820604324, -0.003332088701426983, -0.06009811908006668, 0.098154217004776, -0.09206710755825043, -0.0632794201374054, -0.05488213524222374, 0.15653489530086517, 0.02736220881342888, -0.012801773846149445, 0.09129811823368073, 0.06342355906963348, -0.1072457879781723, -0.2519654631614685, 0.05138558894395828, -0.06706717610359192, 0.07655152678489685, -0.013825172558426857, 0.12114902585744858, 0.0905885249376297, -0.0062204631976783276, 0.02008623071014881, 0.022685427218675613, -0.22547677159309387, -0.05072670802474022, 0.04517534747719765, 0.06897882372140884, -0.16776692867279053, 0.028761178255081177, 0.04584325850009918, 0.021672045812010765, 0.01878410391509533, 0.06081785634160042, 0.11045703291893005, -0.07791703939437866, 0.021183958277106285, -0.21228837966918945, -0.005711515434086323, -0.027654431760311127, -0.270656943321228, 0.15606579184532166, 0.12996172904968262], "changes": {"1wk": 1.2000020345052083, "1mo": -22.533334096272785}}, {"text": "4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS 4D Molecular Therapeutics, Inc. Mon, Dec 16, 2024, 4:00 PM 7 min read In This Article: FDMT +5.89% 4D Molecular Therapeutics, Inc. Landmark publication in leading ophthalmology research journal demonstrates the power of 4DMT\u2019s Therapeutic Vector Evolution platform to invent potentially best-in-class customized vectors and transformative genetic medicines Proprietary intravitreal vector R100 demonstrated superior transduction and transgene expression compared to AAV2, the standard AAV serotypes used in retinal gene therapies, in all three human retinal cell types evaluated in vitro (up to ~10-fold improvement), and in all primate retinal cell layers after intravitreal injection in vivo Intravitreal administration of the R100 vector-based 4D-150 genetic medicine in nonhuman primate wet AMD model was well tolerated, led to robust retinal expression of dual transgenes (aflibercept and anti-VEGF C) and complete suppression of severe CNV choroidal neovascularization lesions 4D-150 wet AMD (PRISM) and DME (SPECTRA) Phase 1/2 clinical trials are currently underway; 4FRONT Phase 3 program in wet AMD on target to initiate in Q1 2025 EMERYVILLE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics\u00a0(Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced the publication of landmark preclinical data demonstrating the potential of the Company\u2019s proprietary Therapeutic Vector Evolution (TVE) platform, intravitreal R100 vector and the R100-based genetic medicine 4D-150. Pioneering efficacy and safety results in a difficult-to-treat nonhuman primate (NHP) model of wet age-related macular degeneration (wet AMD) demonstrated the potential of 4D-150 to substantially reduce the treatment burden and improve long-term vision outcomes for patients with wet AMD, diabetic macular edema (DME) and diabetic retinopathy (DR). The data were published in Investigative Ophthalmology & Visual Science ( IOVS ); December 2024 issue. IOVS is the journal of the Association for Research in Vision and Ophthalmology (ARVO), a leading basic and translational research association in ophthalmology. The publication entitled, \u201cDesign and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies,\u201d reports the results of preclinical discovery, engineering and characterization studies evaluating the safety, retinal cell transduction, transgene expression and clinical activity of proprietary evolved intravitreal vector R100 and 4D-150, an R100-based genetic medicine carrying 2 therapeutic transgenes: 1) a codon-optimized sequence encoding aflibercept, a recombinant protein that inhibits VEGF-A, VEGF-B and PlGF, and 2) a microRNA sequence that inhibits expression of VEGF-C. The data showed that R100 demonstrated significantly superior human retinal cell transduction compared to AAV2, and intravitreal administration of 4D-150 to nonhuman primates was well tolerated and led to robust panretinal expression of both transgenes, especially within the macula region; AAV2 was unable to transduce deep retinal cell layers in the same model. In a difficult-to-treat primate laser-induced choroidal neovascularization model of wet AMD, 4D-150 completely prevented grade IV angiogenic lesions at all tested doses. Story Continues \u201cWe founded 4DMT with the belief that the Nobel Prize-winning technology of directed evolution could be applied to invent highly optimized and customized AAV vectors for any tissue in the body. This proprietary Therapeutic Vector Evolution approach has been validated through clinical results with three different proprietary vectors for transgene payload delivery to the retina (R100, intravitreal), lung airways (A101, aerosol) and heart (C102, intravenous). R100 was invented to be a potentially best-in-class intravitreal vector to address and overcome the limitations of conventional vectors for the retina, and we are now leveraging R100 in our 4D-150 product candidate to potentially bring to market the first large market genetic medicine to transform vision outcomes for millions of patients with wet AMD and diabetic eye diseases,\u201d said David Kirn, M.D., senior author of the paper and Co-founder and Chief Executive Officer of 4DMT. \u201cThis innovative disease-modifying genetic medicine is designed to continuously suppress all four major molecular drivers of these diseases for years, directly at the site of the disease within the macula, following a single routine clinic-based intravitreal injection. Standard of care bolus anti-VEGF therapies, which generate billions in annual sales, cannot achieve this transformative mechanism of action. The robust results in our primate models reinforce our confidence in 4D-150's efficacy in patients.\u201d The publication is available online at the IOVS website and on the Scientific Publications page of the 4DMT website. About 4D-150 4D-150 combines our customized and evolved intravitreal vector, R100, and a transgene cassette that expresses both aflibercept and a VEGF-C inhibitory RNAi. This dual-transgene payload inhibits four members of the VEGF angiogenic family of factors that drive wet AMD and DME: VEGF A, B, C and PlGF. R100 was invented at 4DMT through our proprietary Therapeutic Vector Evolution platform; we developed this platform utilizing principles of directed evolution, a Nobel Prize-winning technology. 4D-150 is designed for single, low-dose intravitreal delivery for transgene expression from the retina without significant inflammation. About Wet AMD Wet AMD is a highly prevalent disease with estimated incidence rate of 200,000 new patients per year in the United States. It is estimated that the total prevalence of wet AMD in certain major markets, including the United States and the European Union (major markets), and Japan, will be greater than 4 million individuals in the next five years. Wet AMD is a type of macular degeneration where abnormal blood vessels (choroidal neovascularization or CNV) grow into the macula, the central area of the retina. As a consequence, CNV causes swelling and edema of the retina, bleeding and scarring, and causes visual distortion and reduced visual acuity. The proliferation and leakage of abnormal blood vessels is stimulated by VEGF. This process distorts and can potentially destroy central vision and may progress to blindness without treatment. About DME DME is a highly prevalent disease with significant unmet medical need. It is estimated that there are approximately one million individuals with DME in the United States according to published data. DME is characterized by swelling in the macula due to leakage from blood vessels, which can lead to blurred vision. DME is typically treated with intravitreal anti-VEGF agents administered approximately every 4-12 weeks. About 4DMT 4DMT is a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT\u2019s proprietary invention platform, Therapeutic Vector Evolution, combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our product design, development, and manufacturing engine helps us efficiently create and advance our diverse product pipeline with the goal of revolutionizing medicine with potential curative therapies for millions of patients. Currently, 4DMT is advancing six clinical-stage and one preclinical product candidate, each tailored to address rare and large market diseases in ophthalmology, pulmonology and cardiology. In addition, 4DMT is also advancing programs in CNS through a gene editing partnership. 4D Molecular Therapeutics\u2122, 4DMT\u2122, Therapeutic Vector Evolution\u2122, and the 4DMT logo are trademarks of 4DMT. All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied. Learn more at www.4DMT.com and follow us on LinkedIn . Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the therapeutic potential, and clinical benefits and market potential of 4DMT\u2019s product candidates, and its R100, A101 and C102 vectors, as well as the plans, announcements, and related timing for the clinical development of, regulatory interactions regarding, and potential commercialization of 4D-150. The words \"may,\" \u201cmight,\u201d \"will,\" \"could,\" \"would,\" \"should,\" \"expect,\" \"plan,\" \"anticipate,\" \"intend,\" \"believe,\" \u201cexpect,\u201d \"estimate,\" \u201cseek,\u201d \"predict,\" \u201cfuture,\u201d \"project,\" \"potential,\" \"continue,\" \"target\" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including risks and uncertainties that are described in greater detail in the section entitled \"Risk Factors\" in 4D Molecular Therapeutics\u2019 most recent Quarterly Report on Form 10-Q as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent 4D Molecular Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. 4D Molecular Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward looking statements. Contacts: Media: Katherine Smith Inizio Evoke Comms Media@4DMT.com Investors: Julian Pei Head of Investor Relations and Corporate Finance Investor.Relations@4DMT.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "FDMT", "date": "2024-12-16T13:00:00+00:00", "sentiment": {"score": 0.7879273826256394, "confidence": 0.7962618470191956, "probabilities": {"positive": 0.7962618470191956, "negative": 0.008334464393556118, "neutral": 0.19540373980998993}}, "embedding": [-0.03946518898010254, -0.10394954681396484, 0.08299127221107483, -0.09097689390182495, -0.00537479855120182, -0.13298264145851135, -0.09573118388652802, 0.21373888850212097, 0.0033938325941562653, 0.2555702328681946, -0.17676424980163574, 0.0250086709856987, -0.005412010475993156, 0.1600632220506668, -0.13820894062519073, 0.14353901147842407, -0.15978151559829712, 0.1892302930355072, -0.07339594513177872, 0.0963299423456192, 0.11997253447771072, -0.05826212838292122, 0.082291379570961, -0.0653345137834549, -0.1752089262008667, 0.004615917801856995, 0.10120979696512222, -0.0900825634598732, -0.07484249770641327, -0.1410978138446808, 0.09386499971151352, 0.07493536174297333, -0.0761110931634903, 0.05124453827738762, -0.21012738347053528, -0.0023660133592784405, -0.048847977072000504, -0.0639345645904541, -0.2655937075614929, -0.04090224951505661, -0.10053201019763947, 0.046027809381484985, -0.1418488323688507, 0.14771641790866852, 0.3535915017127991, -0.13143472373485565, -0.12130110710859299, 0.029128236696124077, 0.007790034636855125, 0.2146957963705063, -0.041234202682971954, 0.037516720592975616, -0.15390343964099884, 0.15435194969177246, -0.04759885370731354, 0.05725392699241638, -0.22140410542488098, -0.08558052778244019, 0.26578524708747864, 0.0855749249458313, 0.10837326943874359, -0.07565397024154663, 0.05951985344290733, -0.07228894531726837, 0.055958252400159836, 0.032484058290719986, -0.0377749428153038, -0.11865702271461487, -0.09217989444732666, -0.12208260595798492, 0.017477327957749367, -0.05703502520918846, 0.059002265334129333, 0.03397238254547119, -0.08853153884410858, 0.09185205399990082, 0.2449904978275299, 0.11511735618114471, 0.016520675271749496, -0.08820776641368866, 0.1379874348640442, 0.13022536039352417, 0.11539226770401001, -0.09591597318649292, 0.15334072709083557, 0.1811615526676178, -0.07900546491146088, -0.013342642225325108, 0.09298844635486603, 0.08530054241418839, -0.05788928270339966, 0.054077763110399246, -0.048437491059303284, 0.04758664220571518, -0.06532936543226242, -0.034980688244104385, 0.07464055716991425, -0.050945766270160675, 0.12780418992042542, 0.024703681468963623, 0.0022237119264900684, -0.002369225723668933, -0.0952058956027031, 0.01014341227710247, 0.011700903996825218, -0.18753576278686523, 0.28534597158432007, 0.06739744544029236, -0.040562279522418976, -0.08651593327522278, 0.04497373104095459, 0.20015162229537964, -0.02227175422012806, 0.15694859623908997, -0.13795748353004456, 0.1415838599205017, -0.1497838944196701, -0.028633292764425278, 0.34337231516838074, -0.052572645246982574, -0.050040505826473236, 0.1622663140296936, 0.11934850364923477, -0.04695165529847145, 0.14018478989601135, 0.06027814373373985, -0.06351518630981445, 8.777314931202262e-33, -0.10656470060348511, 0.025333348661661148, 0.032089293003082275, 0.13688573241233826, -0.011562281288206577, -0.13219135999679565, 0.16649572551250458, 0.07734958827495575, -0.3256490230560303, -0.07314349710941315, -0.23706814646720886, -0.06822770833969116, -0.002416450995951891, 0.2861453890800476, -0.05798184126615524, -0.0847526341676712, 0.10935530811548233, -0.029189448803663254, -0.021221697330474854, -0.135860413312912, -0.028950940817594528, 0.14819103479385376, -0.06093905493617058, 0.08459699153900146, 0.026127947494387627, 0.06314004957675934, -0.06382578611373901, 0.02590176835656166, 0.11042290180921555, 0.08739357441663742, -0.2857525944709778, 0.12596440315246582, 0.0780828446149826, -0.15255530178546906, -0.018524544313549995, -0.010171465575695038, 0.09980488568544388, -0.18159997463226318, 0.022484581917524338, 0.07815835624933243, -0.060937680304050446, 0.05730367824435234, -0.12695220112800598, -0.16867253184318542, 0.06231417879462242, 0.03174649924039841, 0.04547564685344696, 0.09007561206817627, -0.1718721240758896, -0.045396588742733, -0.07187720388174057, 0.0639122873544693, 0.02638978511095047, -0.05931349843740463, -0.13026224076747894, -0.02264951914548874, -0.26362118124961853, -0.0318019837141037, 0.06059645861387253, 0.06430482119321823, -0.008028939366340637, 0.0609407052397728, -0.13533441722393036, 0.15639758110046387, -0.01600593328475952, -0.1710701584815979, 0.21339693665504456, -0.03312180936336517, -0.055147022008895874, 0.06956455856561661, 0.13852903246879578, -0.03749587759375572, 0.20640017092227936, -0.08104554563760757, 0.21445739269256592, 0.06107623502612114, 0.11131872236728668, 0.2198205441236496, -0.03773694485425949, -0.0012455526739358902, -0.15096332132816315, 0.31482940912246704, -0.18810197710990906, 0.044644590467214584, 0.1290222406387329, -0.09429433196783066, 0.16821637749671936, 0.08171364665031433, -0.08821263909339905, -0.08831854164600372, 0.2283841371536255, -0.08435985445976257, -0.053055793046951294, -0.12371782958507538, 0.018881674855947495, -9.984384529655575e-33, -0.18141409754753113, 0.04500482976436615, -0.043749626725912094, -0.022358817979693413, -0.1920669674873352, 0.18550091981887817, 0.1227363720536232, -0.04584457725286484, 0.14989453554153442, -0.33776891231536865, 0.09717942774295807, -0.034625712782144547, -0.07920023798942566, -0.169852614402771, -0.12921564280986786, 0.09342046827077866, -0.2932150959968567, -0.0822097435593605, -0.1231648176908493, 0.07232442498207092, 0.10489518940448761, 0.24987351894378662, 0.015647459775209427, 0.018103480339050293, 0.15293744206428528, 0.004965520463883877, 0.1468745619058609, 0.11984775960445404, -0.06380786001682281, 0.034508079290390015, -0.1442292332649231, 0.13312211632728577, -0.23248250782489777, 0.08771507441997528, -0.005613310262560844, 0.04213716834783554, -0.03175286576151848, -0.17455130815505981, -0.14424185454845428, -0.016571763902902603, 0.03193109482526779, 0.1382664144039154, -0.05723082646727562, -0.10262294113636017, -0.01664942502975464, 0.10759103298187256, 0.11345082521438599, 0.09962578117847443, 0.22375068068504333, 0.01988895982503891, -0.06735941767692566, -0.04933178424835205, -0.022206328809261322, -0.0883893072605133, -0.09585204720497131, -0.15584999322891235, 0.06364618986845016, -0.02848096378147602, -0.06905937939882278, 0.03973720967769623, 0.029244160279631615, -0.18664497137069702, 0.1988823115825653, -0.04715918377041817, 0.10778800398111343, 0.13459035754203796, 0.1046125590801239, 0.12267608940601349, 0.13616855442523956, -0.12705254554748535, -0.061467111110687256, -0.18958738446235657, -0.07333701848983765, -0.04897723346948624, 0.0640401691198349, 0.013571097515523434, 0.028802473098039627, -0.11112506687641144, -0.22151166200637817, -0.012039671652019024, 0.035874269902706146, -0.045941151678562164, -0.08859151601791382, 0.15021482110023499, 0.04655374214053154, 0.04518289119005203, 0.10893093049526215, -0.05193141847848892, 0.04428962990641594, 0.041510917246341705, -0.1672869622707367, -0.11216375231742859, -0.2642490863800049, 0.13725942373275757, -0.13079160451889038, -9.985804183543223e-08, 0.13678193092346191, 0.07402236759662628, -0.019278494641184807, -0.10749715566635132, 0.024235671386122704, 0.017163781449198723, -0.1707257330417633, 0.09159674495458603, -0.07075969874858856, 0.0796683058142662, -0.08962215483188629, 0.14838075637817383, -0.06987481564283371, 0.05417820066213608, 0.05960337817668915, 0.03927699849009514, -0.09894292056560516, 0.039084598422050476, -0.03144356608390808, -0.05233968049287796, -0.163324773311615, 0.08027409762144089, 0.007262859493494034, 0.013490147888660431, 0.02048061229288578, -0.00047142623225227, -0.001954376697540283, -0.011589324101805687, 0.16159312427043915, -0.14915095269680023, 0.11121208965778351, 0.018161725252866745, 0.09908206760883331, 0.0707492083311081, -0.10088316351175308, -0.1681806743144989, -0.029288645833730698, 0.23249025642871857, 0.037430740892887115, 0.2331966906785965, -0.07657776772975922, -0.007094317581504583, 0.05390602722764015, 0.05410771816968918, -0.1910535842180252, -0.0016654501669108868, -0.046765346080064774, -0.015273714438080788, -0.0166043508797884, -0.0989651083946228, -0.2059374749660492, -0.09275782853364944, -0.05914871394634247, -0.13052624464035034, -0.16882292926311493, 0.037292517721652985, -0.04682374745607376, -0.05838701128959656, -0.0218658410012722, -0.24180513620376587, -0.01386626623570919, 0.006424722261726856, 0.025631967931985855, 0.014551570639014244], "changes": {"1wk": -2.623457959777167, "1mo": -24.69135648029423}}, {"text": "4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV 4D Molecular Therapeutics, Inc. Thu, Nov 14, 2024, 4:00 PM 2 min read In This Article: FDMT +5.89% 4D Molecular Therapeutics, Inc. EMERYVILLE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in November and December and will present at the Ophthalmology Innovation Summit XIV. Members of the management team will also be available for one-on-one meetings at the respective investor conferences. Jefferies London Healthcare Conference 2024 Presentation Date: Tuesday, November 19, 2024 Presentation Time: 12:00 p.m. GMT Webcast Link: Webcast 7th Annual Evercore ISI HealthCONx Conference Presentation Date: Tuesday, December 3, 2024 Presentation Time: 1:45 p.m. ET Webcast Link: Webcast Archived copies of the webcasts will be available for up to one year by visiting the \u201cInvestors\u201d section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events . Ophthalmology Innovation Summit XIV Session Title: Gene & Cell Therapy Showcase Presenter: Carlos Quezada-Ruiz, M.D., FASRS, SVP, Therapeutic Area Head, Ophthalmology Presentation Date: Friday, November 22, 2024 Presentation Time: 4:40 p.m. PT About 4DMT 4DMT is a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT\u2019s proprietary invention platform, Therapeutic Vector Evolution, combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our product design, development, and manufacturing engine helps us efficiently create and advance our diverse product pipeline with the goal of revolutionizing medicine with potential curative therapies for millions of patients. Currently, 4DMT is advancing six clinical-stage and one preclinical product candidate, each tailored to address rare and large market diseases in ophthalmology, pulmonology and cardiology. In addition, 4DMT is also advancing programs in CNS through a gene editing partnership. 4D Molecular Therapeutics\u2122, 4DMT\u2122, Therapeutic Vector Evolution\u2122, and the 4DMT logo are trademarks of 4DMT. All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied. Story Continues Learn more at www.4DMT.com and follow us on LinkedIn . Contacts: Media: Katherine Smith Inizio Evoke Comms Media@4DMT.com Investors: Julian Pei Head of Investor Relations and Corporate Finance Investor.Relations@4DMT.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "FDMT", "date": "2024-11-14T13:00:00+00:00", "sentiment": {"score": 0.14321935456246138, "confidence": 0.15164241194725037, "probabilities": {"positive": 0.15164241194725037, "negative": 0.00842305738478899, "neutral": 0.8399345874786377}}, "embedding": [-0.03484393283724785, -0.10122097283601761, -0.04852283373475075, -0.08624281734228134, -0.03121541067957878, -0.13610124588012695, -0.005682206712663174, 0.19313085079193115, 0.05977817624807358, 0.07119153439998627, -0.14032064378261566, 0.026156267151236534, -0.06570446491241455, 0.11422692239284515, -0.11858348548412323, 0.08403138816356659, -0.11178804934024811, -0.044264502823352814, -0.05245077237486839, -0.06716064363718033, -0.041209954768419266, 0.05991195887327194, 0.18870961666107178, -0.017032260075211525, -0.13576331734657288, -0.04802931845188141, -0.016745014116168022, -0.10763183236122131, -0.06920120120048523, -0.11753973364830017, 0.09600412100553513, 0.12365026026964188, 0.06039479374885559, 0.009936746209859848, -0.0941375344991684, 0.045170608907938004, -0.10720433294773102, -0.02410878986120224, -0.06889994442462921, 0.0626603364944458, -0.019899869337677956, 0.033776916563510895, -0.15009576082229614, 0.09704528748989105, 0.09346850216388702, -0.09350882470607758, -0.062400899827480316, -0.04528764262795448, 0.03212704136967659, 0.19993063807487488, -0.0909905880689621, -0.08999504894018173, -0.009172627702355385, 0.03908827528357506, -0.06715478748083115, 0.07491464912891388, -0.24636982381343842, -0.06062762066721916, 0.03360133618116379, 0.02342372201383114, 0.1379292905330658, -0.028014397248625755, -0.09510041773319244, 0.027603285387158394, 0.009042810648679733, 0.07835504412651062, 0.07639239728450775, 0.02912820130586624, 0.019984319806098938, -0.1493327021598816, 0.037112731486558914, 0.02458707056939602, 0.11296332627534866, 0.07370032370090485, -0.06373456865549088, 0.09092722833156586, 0.17635974287986755, -0.03500087186694145, 0.1059643030166626, 0.04929465055465698, 0.1363876760005951, 0.036447666585445404, 0.1685301661491394, -0.043079860508441925, -0.024702178314328194, 0.08475066721439362, -0.038221973925828934, 0.02953731268644333, 0.03663555160164833, 0.026491625234484673, -0.06680549681186676, 0.04758458957076073, -0.03956005722284317, -0.007115254178643227, -0.1057816743850708, 0.056853387504816055, 0.06003427505493164, -0.04523981362581253, 0.07289841771125793, 0.08525249361991882, -0.020735803991556168, -0.04635227471590042, -0.08151870220899582, -0.038498926907777786, -0.08373869955539703, -0.14428521692752838, 0.12439887225627899, 0.008925145491957664, -0.028001300990581512, -0.01495315320789814, -0.06142665445804596, 0.13789179921150208, 0.0009926743805408478, -0.04883904755115509, -0.0944424495100975, 0.17538312077522278, -0.11830462515354156, -0.01592797227203846, 0.11953600496053696, -0.02671722322702408, -0.0767347514629364, 0.12830612063407898, 0.09641647338867188, -0.07283759117126465, 0.03984013572335243, 0.04229533299803734, -0.14154061675071716, 1.3530580622385727e-32, -0.0389041006565094, 0.1571020483970642, 0.09695892035961151, 0.11063732206821442, 0.04222438484430313, 0.00878946203738451, 0.0793929249048233, -0.028471939265727997, -0.29331520199775696, -0.07631555199623108, -0.14119002223014832, -0.07524056732654572, 0.013076964765787125, 0.12460954487323761, -0.04647256061434746, -0.17012947797775269, 0.06588786840438843, 0.07745629549026489, 0.02701653726398945, -0.13458332419395447, -0.01879521645605564, 0.10086067765951157, -0.0673484280705452, 0.19849568605422974, 0.001241285353899002, 0.07960160821676254, 0.0009407862089574337, 0.021072763949632645, 0.16588115692138672, 0.08185972273349762, -0.2828845977783203, 0.10371814668178558, -0.06745831668376923, -0.16843482851982117, -0.025867287069559097, -0.029596399515867233, -0.07572510093450546, -0.23025977611541748, 0.06901825219392776, 0.07326474040746689, -0.14051136374473572, 0.00022709066979587078, -0.0596885085105896, -0.16692297160625458, 0.031704455614089966, 0.05992435663938522, -0.13889309763908386, 0.11838603764772415, -0.003431587480008602, 0.07832886278629303, -0.07916739583015442, -0.026958422735333443, 0.0720142349600792, -0.03074776381254196, 0.054801538586616516, -0.013206078670918941, -0.228601336479187, -0.08263306319713593, 0.10891224443912506, 0.12342527508735657, 0.09156277030706406, 0.04129619151353836, -0.17197951674461365, 0.05397764593362808, -0.10429192334413528, -0.039252351969480515, 0.052183907479047775, -0.05463758856058121, -0.06811567395925522, 0.12401808053255081, 0.04524242505431175, -0.05522022396326065, 0.13985496759414673, -0.025736477226018906, 0.18645769357681274, 0.0012030177749693394, 0.04451490938663483, 0.1659073531627655, -0.043498724699020386, 0.05106822028756142, -0.07839490473270416, 0.12384060025215149, -0.07040004432201385, 0.10959012806415558, 0.05545901134610176, -0.1655733734369278, 0.12798288464546204, 0.08603256940841675, -0.10253413766622543, 0.0359983928501606, 0.043883129954338074, -0.15846887230873108, -0.03822796419262886, 0.08075462281703949, 0.027188485488295555, -1.3291592335287987e-32, -0.02048792503774166, 0.037331245839595795, -0.06956075131893158, -0.05807947367429733, 0.018270345404744148, 0.08373114466667175, 0.06647813320159912, 0.024406658485531807, 0.0948585569858551, -0.09643948078155518, 0.15343186259269714, 0.002403993159532547, -0.043285541236400604, -0.1062503457069397, -0.11877477914094925, 0.049788329750299454, -0.05765692889690399, -0.16148188710212708, -0.07278820872306824, 0.09730812907218933, 0.07888912409543991, 0.13855215907096863, -0.14392612874507904, 0.02039327099919319, 0.04751831293106079, 0.02270815521478653, 0.1743660271167755, 0.10480828583240509, -0.016497716307640076, 0.06849967688322067, -0.13461577892303467, 0.044620953500270844, -0.2563971281051636, 0.10478222370147705, -0.03341938555240631, 0.06290564686059952, 0.13150562345981598, -0.08583670854568481, -0.06119156628847122, -0.13299275934696198, 0.10415908694267273, -0.007801340892910957, 0.011163517832756042, 0.08331513404846191, 0.06828732788562775, 0.04738195985555649, 0.017093030735850334, 0.0030368096195161343, 0.16330987215042114, -0.028306949883699417, -0.05666419491171837, 0.003895448986440897, 0.048921480774879456, -0.10791380703449249, -0.06544490158557892, -0.10184328258037567, 0.022067777812480927, -0.05549532175064087, -0.02861657366156578, -0.007938729599118233, -0.039674755185842514, -0.14899198710918427, 0.12570720911026, 0.10810260474681854, 0.08692502975463867, -0.04505450278520584, 0.079708531498909, 0.05383819341659546, 0.038206350058317184, -0.07912030071020126, -0.02085832506418228, -0.09160280227661133, -0.01690565049648285, -0.04085153341293335, 0.05997439846396446, 0.06672583520412445, -0.0645933747291565, -0.07961910218000412, -0.11271651089191437, 0.05649406462907791, 0.08036008477210999, -0.01490538939833641, 0.031457945704460144, 0.1132187694311142, 0.07856231182813644, 0.01992093026638031, 0.1195291131734848, 0.06741541624069214, -0.06839443743228912, -0.02232462167739868, -0.04198675602674484, -0.029372846707701683, -0.06118312478065491, 0.10785962641239166, 0.08968248218297958, -1.0102383640742119e-07, 0.11346180737018585, -0.0003445160109549761, -0.04929685592651367, -0.12107159197330475, -0.02108084224164486, -0.031018322333693504, -0.11022506654262543, 0.05220162123441696, -0.028299741446971893, 0.09012725204229355, -0.05495227128267288, 0.24647599458694458, -0.08679725229740143, 0.07012809813022614, 0.030852731317281723, -0.03929441049695015, -0.18799787759780884, -0.0021137839648872614, -0.05556486174464226, -0.16428935527801514, -0.13702687621116638, 0.048711519688367844, 0.014493433758616447, 0.029304608702659607, 0.04723796993494034, -0.028637781739234924, -0.03099466860294342, -0.004963528830558062, 0.07679799944162369, -0.06255693733692169, 0.03190615400671959, 0.019915394484996796, -0.008287366479635239, -0.009417692199349403, -0.037722308188676834, -0.20121753215789795, -0.04788273200392723, 0.07735591381788254, 0.07703375071287155, 0.16580229997634888, -0.016278279945254326, -0.018057508394122124, 0.06178683042526245, 0.058616623282432556, -0.15191446244716644, -0.07309181988239288, 0.01378332357853651, -0.030010366812348366, 0.07686487585306168, -0.10545846074819565, -0.1120811402797699, -0.05049759894609451, -0.01915532350540161, -0.08347053080797195, -0.0897139459848404, 0.1285395473241806, -0.04465693235397339, -0.02702413685619831, -0.03783584386110306, -0.1196100264787674, -0.018458891659975052, -0.13276296854019165, 0.0094674713909626, 0.07895896583795547], "changes": {"1wk": 4.862835004839718, "1mo": -18.952623079868435}}, {"text": "4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones 4D Molecular Therapeutics, Inc. Thu, Nov 14, 2024, 12:05 AM 10 min read In This Article: FDMT +5.89% 4D Molecular Therapeutics, Inc. Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populations and intraocular inflammation (IOI) profile numerically similar to approved anti-VEGF agents 4D-150 4FRONT Phase 3 program in wet AMD designed to maximize probability of success, continues to be on track with 4FRONT-1 trial initiation expected in Q1 2025 Continuing KOL engagement to expand awareness of the potential differentiated product profile of 4D-150 Company product portfolio strategy and cash utilization updates, together with SPECTRA clinical trial program and interim data updates in diabetic macular edema (DME), expected in early January 2025 $551 million in cash, cash equivalents and marketable securities as of September 30, 2024, expected to fund planned operations at least into H1 2027, with update expected as noted above in early January 2025 EMERYVILLE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics\u00a0(Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today reported third quarter 2024 financial results, provided operational highlights and outlined expected upcoming milestones. \u201cThroughout 2024, 4DMT has generated compelling Phase 1/2 data and executed on Phase 3 preparations for 4D-150 in wet AMD in support of our mission to bring transformative genetic medicines to patients globally. We have built an experienced clinical and commercial team to execute this mission, including with the upcoming initiation of the 4FRONT Phase 3 program expected in Q1 2025,\u201d said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. \u201cIn September, we hosted our 4D-150 Wet AMD Development Day, where we presented positive interim data demonstrating the impressive tolerability and clinical activity of 4D-150 and showcased its potential across multiple populations, from the most severe to recently diagnosed patients. The strong data and enthusiastic feedback from our advisors, clinical trial investigators, the retina physician community and the FDA support pivotal development of 4D-150 in the treatment na\u00efve wet AMD population. We believe that these clinical data and this trial design will enable rapid enrollment and achieve positive topline data in the 4FRONT Phase 3 studies.\u201d Recent Corporate Highlights Bolstered Senior Ophthalmology Leadership Team: Dhaval Desai, PharmD, joined as Chief Development Officer; overseeing late-stage product development, Medical Affairs, Scientific Communications, Regulatory and Quality operations. Dr. Desai was most recently SVP & Chief Development Officer at Iveric Bio (an Astellas company), where he led development and approval of IZERVAY Christopher Simms joined as Chief Commercial Officer; overseeing Pre-commercial and Commercial organizations and pre-launch preparations and development. Mr. Simms was most recently SVP & Chief Commercial Officer at Iveric Bio (an Astellas company), where he led commercial strategy and execution for the launch of IZERVAY Carlos Quezada-Ruiz, M.D., FASRS, joined as SVP, Therapeutic Area Head, Ophthalmology; leading the Ophthalmology franchise and overseeing early- and late-stage clinical development. Dr. Quezada-Ruiz was most recently Group Medical Director, Ophthalmology at Genentech, where he led clinical development and approval of VABYSMO and SUSVIMO Story Continues Formed Ophthalmology Advisory Board comprised of world-renowned retina specialists and thought leaders to support development strategy and registration across large market ophthalmology indications including wet AMD, DME, diabetic retinopathy, and geographic atrophy: Dr. Arshad Khanani (Chair), Dr. David Boyer, Dr. Frank Holz, Dr. Anat Loewenstein and Dr. Dante Pieramici Expanded Scientific Advisory Board with Three New Members: John P. Atkinson, M.D. , is Samuel B. Grant Professor of Clinical Medicine at Washington University Division of Biology and Biomedical Sciences. He is a leading expert in rheumatology and innate immunity, specifically the complement system\u2019s role in infectious, autoimmune and inflammatory diseases Napoleone Ferrara, M.D. , is currently Distinguished Professor of Pathology and Adjunct Professor of Ophthalmology and Pharmacology at University of California, San Diego. He is also the Hildyard Endowed Chair in Eye Disease. His main research interests are the biology of angiogenesis and its regulators. His discovery of VEGF as a key mediator of angiogenesis associated with intraocular neovascular syndromes resulted in the clinical development of ranibizumab, which was approved as the first therapy for wet AMD. He was awarded the Lasker\u2013DeBakey Clinical Medical Research Award in 2010 Wenchao Song, Ph.D. , is a Professor of Pharmacology in the Department of Systems Pharmacology and Translational Therapeutics at the Perelman School of Medicine of the University of Pennsylvania. Dr. Song is an internationally renowned expert on complement biology. His research group pioneered studies of mouse models of complement-mediated diseases. His work has helped reveal fundamental knowledge of how complement is regulated in vivo, with translational relevance to anti-complement therapeutics More details on our members can be found in the SAB section of our website Recent Highlights in Large Market Ophthalmology Portfolio 4D-150 for wet AMD: Presented positive interim data from the ongoing PRISM Phase 1/2 clinical trial at 4D-150 Wet AMD Development Day: Robust and durable reduction in anti-VEGF injection treatment burden observed in all populations studied with the planned Phase 3 dose (3E10 vg/eye) through up to 52 weeks, including overall reduction of 83% in severe population and Kaplan-Meier method estimated 52-week injection-free rates of 70% and 87% in broad and recently diagnosed populations, respectively Strong and sustained disease control achieved: stable retinal anatomy with fewer fluctuations and stable visual acuity 4D-150 continues to be safe and well tolerated with rate of IOI numerically similar to that reported for approved anti-VEGF agents and 99% of patients completing topical steroid prophylaxis taper on schedule Presented design of 4FRONT-1 Phase 3 clinical trial at its 4D-150 Wet AMD Development Day: First study in global 4FRONT Phase 3 development program comparing a single dose of 4D-150 3E10 vg/eye to on-label aflibercept 2mg Q8 weeks Eligibility criteria: 1) Patients must be both recently diagnosed and treatment na\u00efve wet AMD patients, and 2) Randomization requires on study demonstration of aflibercept responsiveness Supplemental aflibercept injection criteria for 4D-150 arm optimized to protect primary BCVA endpoint and to maximize reduction of supplemental treatment burden; criteria to be disclosed prior to trial initiation. No supplemental injections allowed in control arm Study design has been aligned with feedback from U.S. Food and Drug Administration (FDA) under RMAT designation Alignment ongoing with European Medicines Agency under PRIME designation Recent Highlights in Other Pipeline Programs 4D-710 for Cystic Fibrosis (CF) Lung Disease: Presented preclinical data for 4D-710 in combination with CFTR modulators in a poster presentation at the 2024 North American Cystic Fibrosis Conference Enrollment continues in AEROW Phase 1 clinical trial 4D-310 for Fabry Disease Cardiomyopathy: FDA removed clinical hold on the Phase 1/2 INGLAXA clinical trial for 4D-310 in Fabry disease cardiomyopathy; trial resumption underway Expected Upcoming Milestones in Large Market Ophthalmology Portfolio 4D-150 for Wet AMD: 52-week interim data from Phase 2b cohort of PRISM clinical trial expected in February 2025 4FRONT-1 Phase 3 clinical trial initiation expected in Q1 2025 4D-150 for DME: SPECTRA clinical trial program and interim data updates expected in early January 2025 4D-175 for Geographic Atrophy: Phase 1 enrollment expected to begin in Q1 2025 Expected Upcoming Milestones in Other Pipeline Programs 4D-710 for CF Lung Disease: Interim data and program update from AEROW clinical trial is expected in mid-2025 4D-725 for Alpha-1-Antitrypsin Deficiency Lung Disease: Program update expected in early January 2025 4D-310 for Fabry Disease Cardiomyopathy: Interim data and program update expected in 2025 4D-110 for Choroideremia and 4D-125 for X-Linked Retinitis Pigmentosa: Program updates expected in early January 2025 Q3 2024 Financial Results Cash position: Cash, cash equivalents and marketable securities were $551 million as of September 30, 2024. We currently expect cash, cash equivalents and marketable securities to be sufficient to fund planned operations at least into the first half of 2027. R&D Expenses: Research and development expenses were $38.5 million for the third quarter of 2024, as compared to $25.1 million for the third quarter of 2023. This increase was driven by the progression of our existing clinical trials, primarily Phase 2 4D-150 trials in wet AMD and DME, along with increased payroll and stock-based compensation expense due to higher headcount. G&A Expenses: General and administrative expenses were $12.7 million for the third quarter of 2024, as compared to $9.1 million for the third quarter of 2023. Net Loss: Net loss was $43.8 million for the third quarter of 2024, as compared to net loss of $10.3 million for the third quarter of 2023. About 4DMT 4DMT is a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT\u2019s proprietary invention platform, Therapeutic Vector Evolution, combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our product design, development, and manufacturing engine helps us efficiently create and advance our diverse product pipeline with the goal of revolutionizing medicine with potential curative therapies for millions of patients. Currently, 4DMT is advancing six clinical-stage and one preclinical product candidate, each tailored to address rare and large market diseases in ophthalmology, pulmonology and cardiology. In addition, 4DMT is also advancing programs in CNS through a gene editing partnership. 4D Molecular Therapeutics\u2122, 4DMT\u2122, Therapeutic Vector Evolution\u2122, and the 4DMT logo are trademarks of 4DMT. All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied. Learn more at www.4DMT.com and follow us on LinkedIn . Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the therapeutic potential and clinical benefits of, as well as the plans, announcements and related timing for the clinical development of, 4DMT\u2019s product candidates, and statements regarding our financial performance, results of operations and anticipated cash runway. The words \"may,\" \u201cmight,\u201d \"will,\" \"could,\" \"would,\" \"should,\" \"expect,\" \"plan,\" \"anticipate,\" \"intend,\" \"believe,\" \u201cexpect,\u201d \"estimate,\" \u201cseek,\u201d \"predict,\" \u201cfuture,\u201d \"project,\" \"potential,\" \"continue,\" \"target\" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including risks and uncertainties that are described in greater detail in the section entitled \"Risk Factors\" in 4D Molecular Therapeutics\u2019 most recent Quarterly Report on Form 10-Q to be filed on or about the date hereof, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent 4D Molecular Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. 4D Molecular Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. 4D Molecular Therapeutics, Inc. Statements of Operations (Unaudited) (in thousands, except share and per share amounts) Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 Revenue: Collaboration and license revenue $ 3 $ 20,204 $ 36 $ 20,742 Operating expenses: Research and development 38,484 25,066 98,212 71,068 General and administrative 12,651 9,112 33,548 25,889 Total operating expenses 51,135 34,178 131,760 96,957 Loss from operations (51,132 ) (13,974 ) (131,724 ) (76,215 ) Other income, net 7,289 3,718 20,527 7,661 Net loss $ (43,843 ) $ (10,256 ) $ (111,197 ) $ (68,554 ) Net loss per share, basic and diluted $ (0.79 ) $ (0.24 ) $ (2.08 ) $ (1.81 ) Weighted-average shares outstanding used in computing net loss per share, basic and diluted 55,554,476 42,256,629 53,377,712 37,884,363 4D Molecular Therapeutics, Inc. Balance Sheet Data (Unaudited) (in thousands) September 30, December 31, 2024 2023 Cash, cash equivalents and marketable securities $ 550,671 $ 299,186 Total assets 604,028 339,891 Total liabilities 51,080 32,062 Accumulated deficit (526,524 ) (415,327 ) Total stockholders\u2019 equity 552,948 307,829 Contacts: Media: Katherine Smith Inizio Evoke Comms Media@4DMT.com Investors: Julian Pei Head of Investor Relations and Corporate Finance Investor.Relations@4DMT.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "FDMT", "date": "2024-11-13T21:05:00+00:00", "sentiment": {"score": 0.7847969140857458, "confidence": 0.7932419776916504, "probabilities": {"positive": 0.7932419776916504, "negative": 0.00844506360590458, "neutral": 0.19831295311450958}}, "embedding": [-0.045240335166454315, -0.08079451322555542, 0.07461971044540405, -0.12056533247232437, 0.035105910152196884, -0.15217147767543793, -0.1266690194606781, 0.2093237340450287, 0.07993661612272263, 0.17087849974632263, -0.14317621290683746, 0.05698832869529724, -0.03871819004416466, 0.0799005776643753, -0.0812956839799881, 0.08182460069656372, -0.0973910242319107, -0.022969575598835945, -0.11518310755491257, 0.037445031106472015, 0.013236664235591888, -0.020726576447486877, 0.14568659663200378, 0.0017269905656576157, -0.08678336441516876, 0.0037372091319411993, 0.02408391423523426, -0.1286749392747879, -0.11336758732795715, -0.08907818794250488, 0.11219972372055054, 0.21359467506408691, 0.017047764733433723, -0.056445688009262085, -0.036880869418382645, -0.0023819145280867815, -0.059620004147291183, -0.06762737035751343, -0.1767200380563736, 0.000757426954805851, -0.010889294557273388, -0.03518417477607727, -0.09752905368804932, 0.2011459469795227, 0.19623908400535583, -0.17757248878479004, -0.1075638085603714, -0.0013871043920516968, 0.06296022236347198, 0.14520686864852905, -0.028829144313931465, -0.09099400043487549, -0.03382601588964462, 0.06343227624893188, -0.05113101750612259, 0.06459275633096695, -0.14209550619125366, -0.0812048614025116, 0.047697484493255615, 0.11434140801429749, 0.15107089281082153, -0.07361739873886108, -0.004882661160081625, -0.03549622744321823, 0.11778493970632553, 0.09836973249912262, 0.032741498202085495, -0.09066657721996307, -0.03362315148115158, -0.1540297269821167, 0.08192476630210876, -0.021038871258497238, 0.08023103326559067, 7.198192179203033e-05, -0.015115524642169476, 0.09143586456775665, 0.17059403657913208, 0.09337575733661652, 0.09675909578800201, -0.09656320512294769, 0.1414094865322113, 0.09801612049341202, 0.17071345448493958, -0.1578853726387024, 0.04574546962976456, 0.06185506656765938, -0.044330619275569916, 0.05914991348981857, 0.0020633104722946882, 0.021306810900568962, 0.006994334980845451, -0.01476878672838211, -0.09707909822463989, 0.06277935951948166, -0.11458928883075714, 0.02954229712486267, -0.03396226838231087, -0.15881487727165222, 0.06626862287521362, 0.02275971882045269, -0.008958309888839722, 0.017693698406219482, -0.09433025121688843, -0.08240878582000732, -0.05680152028799057, -0.16859136521816254, 0.16655784845352173, -0.024279780685901642, -0.06088009849190712, -0.03809233009815216, -0.0625820979475975, 0.06415210664272308, 0.06337486207485199, 0.09289823472499847, -0.14496810734272003, 0.21224090456962585, -0.09929531812667847, 0.007545255124568939, 0.26902803778648376, -0.025590362027287483, 0.008286557160317898, 0.0951061099767685, 0.11609314382076263, -0.11812546104192734, 0.08481228351593018, 0.01056098472326994, -0.07130655646324158, 1.2058622188182243e-32, 0.03863515704870224, -0.00017053773626685143, 0.0230986550450325, 0.11578158289194107, -0.05066878721117973, -0.0737290233373642, 0.1296822428703308, -0.0018782280385494232, -0.24193905293941498, -0.10851076245307922, -0.18722060322761536, 0.001197703881189227, -0.04395769163966179, 0.15984582901000977, -0.08878856152296066, -0.24940580129623413, 0.05377466231584549, 0.06507973372936249, 0.015406772494316101, -0.06079450994729996, 0.0342584028840065, 0.10912599414587021, -0.05451896786689758, 0.05149476230144501, 0.003642279887571931, 0.12281396985054016, -0.05000366270542145, 0.062409672886133194, 0.23122937977313995, 0.11452379822731018, -0.3051126003265381, 0.08123340457677841, 0.011239619925618172, -0.12893973290920258, -0.06259338557720184, 0.009934909641742706, -0.09588085114955902, -0.16990604996681213, 0.04152301326394081, 0.10055463016033173, -0.10286900401115417, 0.08194521069526672, -0.05806109309196472, -0.261324942111969, 0.02278880402445793, -0.02178763970732689, -0.08558355271816254, -0.0331820547580719, -0.05776213854551315, 0.009436394087970257, -0.05074472725391388, 0.03757008910179138, 0.031886160373687744, -0.051048144698143005, -0.027061142027378082, -0.023245686665177345, -0.20484474301338196, -0.14527803659439087, 0.07211083173751831, 0.14095762372016907, -0.00034139095805585384, 0.056292805820703506, -0.15001097321510315, 0.07084625214338303, -0.14763984084129333, 0.037453409284353256, 0.11245962977409363, -0.046222589910030365, -0.13049326837062836, 0.11528226733207703, 0.018223708495497704, -0.08195191621780396, 0.15390482544898987, -0.09547589719295502, 0.22897422313690186, -0.07483924180269241, 0.16237777471542358, 0.16231736540794373, -0.0351906418800354, 0.009334204718470573, -0.040158819407224655, 0.17153266072273254, -0.15480738878250122, 0.15997663140296936, 0.10819052159786224, -0.046528466045856476, 0.11570098996162415, 0.05188969150185585, -0.14936357736587524, -0.05009505897760391, 0.09464726597070694, -0.136746346950531, -0.04510354995727539, 0.06967195868492126, 0.07325344532728195, -1.3782458205040234e-32, -0.07747338712215424, 0.07957674562931061, -0.05431889742612839, -0.07410071790218353, -0.05568833276629448, 0.146135151386261, 0.14858478307724, 0.021651964634656906, 0.14961349964141846, -0.1525808572769165, 0.10923431813716888, -0.0006423257291316986, -0.09375573694705963, -0.07905883342027664, -0.1487836241722107, 0.05054020881652832, -0.1463336944580078, -0.23591673374176025, -0.0860026627779007, 0.12029127776622772, 0.12718497216701508, 0.1567418873310089, -0.09413497149944305, 0.08391731977462769, 0.06847405433654785, 0.03782786801457405, 0.1808825433254242, 0.03162882849574089, -0.08242232352495193, -0.025944918394088745, -0.1706812083721161, 0.020854759961366653, -0.2526140511035919, 0.09619074314832687, -0.06986182928085327, -0.04931391403079033, 0.11732500791549683, -0.13482913374900818, -0.1509329229593277, -0.0540701262652874, 0.041647594422101974, 0.05640185624361038, -0.04909303039312363, 0.025300176814198494, 0.04758225381374359, 0.05427752062678337, 0.05273792892694473, 0.01967262104153633, 0.245721697807312, 0.007454320788383484, -0.033463746309280396, 0.041036635637283325, 0.038507528603076935, -0.050294846296310425, -0.0974501520395279, -0.14963321387767792, 0.07545314729213715, -0.042080555111169815, -0.12348483502864838, 0.10406823456287384, -0.0712733119726181, -0.040344975888729095, 0.13977015018463135, -0.023832568898797035, 0.08037854731082916, 0.03953137993812561, 0.09493990242481232, -0.034787867218256, 0.05061646178364754, -0.050699617713689804, -0.10495453327894211, -0.12169297784566879, -0.07151623070240021, -0.04551934078335762, 0.12217998504638672, 0.02192831039428711, -0.0686081200838089, -0.15806642174720764, -0.1288520246744156, 0.06554136425256729, 0.05370932072401047, -0.03510170429944992, 0.000477377325296402, 0.07870154827833176, 0.04172028601169586, -0.041209813207387924, 0.14470160007476807, 0.009153047576546669, 0.001182137057185173, 0.04044641926884651, -0.10044198483228683, -0.013841996900737286, -0.15016144514083862, 0.17708230018615723, 0.05926673859357834, -1.0096020020000651e-07, 0.1799902617931366, 0.062278300523757935, 0.0047998130321502686, -0.10578460991382599, 0.031181700527668, -0.04253499582409859, -0.08262056112289429, 0.16031306982040405, 0.039984602481126785, 0.04268499091267586, 0.04770843684673309, 0.24106425046920776, -0.18553194403648376, -0.04804343357682228, -0.010823123157024384, 0.06985746324062347, -0.12520338594913483, -0.052869029343128204, -0.04280535876750946, -0.102681964635849, -0.09706497192382812, 0.08904128521680832, 0.01550675742328167, -0.06269185990095139, 0.042653437703847885, -0.017644986510276794, 0.03302067145705223, 0.051664236932992935, 0.04471733421087265, -0.08310144394636154, 0.10152941942214966, -0.029429152607917786, 0.05953006446361542, 0.08500250428915024, -0.15429769456386566, -0.21461951732635498, 0.06144008785486221, 0.18002447485923767, 0.05748215317726135, 0.17666473984718323, -0.04395902156829834, -0.0038575315847992897, -0.03254163637757301, 0.009896339848637581, -0.10374109447002411, -0.05048085004091263, -0.14393958449363708, 0.028787609189748764, 0.04683619737625122, -0.1453077793121338, -0.1319444179534912, -0.05674484372138977, -0.05178815498948097, -0.01576845906674862, -0.050745002925395966, 0.16700464487075806, -0.09002675861120224, -0.03844736889004707, -0.07002866268157959, -0.11223725974559784, 0.025797124952077866, -0.22423046827316284, -0.0070693716406822205, 0.1325361132621765], "changes": {"1wk": 9.079115509750052, "1mo": -15.693904437875789}}, {"text": "PREMIUM RBC Trims Price Target on 4D Molecular Therapeutics to $39 From $40, Keeps Outperform, Speculative Risk MT Newswires Thu, Nov 14, 2024, 2:59 PM In This Article: FDMT +5.89% RBC Trims Price Target on 4D Molecular Therapeutics to $39 From $40, Keeps Outperform, Speculative Risk PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "FDMT", "date": "2024-11-14T11:59:39+00:00", "sentiment": {"score": 0.05033222213387489, "confidence": 0.06423799693584442, "probabilities": {"positive": 0.06423799693584442, "negative": 0.013905774801969528, "neutral": 0.9218562841415405}}, "embedding": [-0.002391587244346738, -0.16076791286468506, -0.06713346391916275, 0.06412999331951141, 0.18606016039848328, 0.014555047266185284, -0.005311098415404558, 0.3952224552631378, 0.08469236642122269, 0.15987040102481842, -0.05511144548654556, 0.06689583510160446, -0.06243452802300453, 0.03703530505299568, 0.0006278462242335081, 0.01883794367313385, 0.06003372743725777, 0.08629126101732254, -0.09450816363096237, 0.08101151883602142, -0.21553575992584229, -0.02187788486480713, 0.10123429447412491, 0.14744260907173157, 0.05195511877536774, -0.10167697072029114, 0.07649700343608856, -0.1618102788925171, -0.0542931854724884, -0.10223497450351715, 0.04036468267440796, -0.0070948489010334015, 0.12380359321832657, -0.10017438977956772, 0.014172040857374668, -0.20036600530147552, -0.15694774687290192, -0.010015053674578667, -0.10479222238063812, 0.0026019469369202852, 0.08465047925710678, -0.06151667609810829, -0.32257556915283203, 0.07376938313245773, -0.14992721378803253, -0.1616942137479782, -0.05692258104681969, 0.1402304768562317, 0.11038626730442047, 0.15072619915008545, 0.04919365420937538, -0.061073046177625656, -0.196400985121727, -0.01869681477546692, -0.03804440423846245, -0.01924302615225315, -0.21416594088077545, -0.06967741996049881, 0.08944444358348846, 0.12516508996486664, 0.020801063627004623, -0.03916660323739052, -0.2031574696302414, -0.03721136599779129, 0.20034009218215942, 0.09446683526039124, 0.10045253485441208, -0.005751717835664749, 0.06281495094299316, -0.02592795342206955, 0.07302325963973999, 0.09843485057353973, 0.06286607682704926, -0.05041833966970444, 0.0642177164554596, 0.1396261304616928, 0.18393105268478394, -0.06075562909245491, 0.0021297335624694824, -0.022279638797044754, 0.041901081800460815, -0.09625851362943649, 0.1539730578660965, -0.010459610261023045, 0.17537052929401398, 0.08461594581604004, 0.04206956550478935, 0.06251776963472366, -0.011367091909050941, -0.049020469188690186, 0.14310286939144135, -0.003845474449917674, 0.002512159524485469, -0.1256181001663208, -0.2381850630044937, -0.019429394975304604, -0.061629075556993484, -0.0663929134607315, -0.05260314792394638, 0.010767610743641853, -0.018603317439556122, -0.07402147352695465, -0.12560205161571503, 0.023405952379107475, -0.07078946381807327, -0.1387440413236618, 0.02386126108467579, 0.18419276177883148, -0.028376678004860878, 0.07607287168502808, -0.10102155804634094, 0.1176392063498497, -0.0018611742416396737, -0.0720859244465828, -0.1437530517578125, 0.1281351000070572, -0.08865692466497421, -0.21659302711486816, 0.18642477691173553, -0.0017993503715842962, -0.09960437566041946, 0.01686497963964939, 0.0014788962434977293, 0.07029803097248077, -0.0819040983915329, -0.13254691660404205, -0.12408673018217087, 1.6909653744523598e-32, 0.009106828831136227, 0.16893194615840912, 0.048162102699279785, -0.16648538410663605, -0.130636066198349, 0.1607096791267395, 0.03414761647582054, -0.15017735958099365, -0.11078768968582153, -0.05480033531785011, -0.09713387489318848, -0.031137678772211075, 0.08739323168992996, 0.054241351783275604, -0.22819527983665466, -0.21101738512516022, -0.0030823410488665104, 0.16746222972869873, 0.11711404472589493, 0.11799484491348267, -0.016159744933247566, 0.09594222903251648, -0.1170567199587822, -0.009669815190136433, -0.08938167989253998, 0.04616161435842514, -0.08681423217058182, 0.061508845537900925, 0.2759300470352173, 0.11841544508934021, -0.3648127615451813, 0.12210909277200699, 0.044843439012765884, -0.14790663123130798, 0.1042998731136322, 0.06697245687246323, -0.06754322350025177, -0.11090118438005447, -0.08613721281290054, -0.071680448949337, -0.038199737668037415, 0.14112325012683868, -0.10555624961853027, -0.15317876636981964, 0.12157344818115234, 0.0235221516340971, -0.07026524096727371, -0.020748309791088104, -0.13698479533195496, 0.10720888525247574, -0.13522861897945404, 0.13949589431285858, -0.009289009496569633, 0.12331119179725647, -0.11312995851039886, -0.27479544281959534, -0.12894271314144135, -0.2817431092262268, 0.07286220788955688, 0.19986732304096222, 0.20725825428962708, 0.1298007071018219, -0.07345039397478104, -0.03024706058204174, -0.05803435668349266, 0.10205104947090149, -0.20162542164325714, -0.06353162229061127, -0.08533059805631638, 0.2470749467611313, 0.09635863453149796, 0.13079537451267242, 0.25710391998291016, -0.1252986490726471, 0.15765002369880676, -0.06634581089019775, 0.012809136882424355, 4.352227915660478e-05, 0.1861601322889328, -0.02172386646270752, -0.05108976364135742, -0.011831560172140598, 0.005947415251284838, 0.02428368851542473, 0.07823574542999268, -0.1595146209001541, -0.10343358665704727, -0.052368342876434326, -0.18591517210006714, -0.019360395148396492, 0.13837988674640656, -0.3062698543071747, -0.18310734629631042, 0.0963861346244812, 0.06202026456594467, -1.5707602037580358e-32, -0.0790671780705452, 0.12963949143886566, 0.14490312337875366, 0.0581805594265461, -0.02163436822593212, 0.03199998661875725, -0.013319108635187149, 0.14164671301841736, 0.15681183338165283, 0.10326088219881058, 0.1372489631175995, 0.10615986585617065, -0.1356355845928192, 0.12144877761602402, -0.04790983721613884, 0.011331029236316681, -0.058925945311784744, -0.2960810661315918, -0.002105914056301117, 0.03893592208623886, -0.1657731980085373, 0.1125122681260109, -0.06284938007593155, 0.33250296115875244, 0.07806601375341415, 0.06466376781463623, 0.08333071321249008, 0.0908893495798111, 0.10024041682481766, -0.006025716662406921, -0.2059997320175171, 0.07780155539512634, -0.20695576071739197, 0.067605160176754, -0.2235279083251953, 0.03296186029911041, 0.21736210584640503, 0.23559758067131042, 0.0007819380844011903, -0.1690215915441513, 0.06295616924762726, 0.020343676209449768, -0.037356745451688766, -0.008079617284238338, 0.12105332314968109, 0.018056871369481087, 0.06157836318016052, 0.19287991523742676, 0.1594555675983429, 0.06074291840195656, -0.023229261860251427, -0.013089308515191078, 0.044816598296165466, 0.07460217922925949, -0.2791273593902588, -0.16000309586524963, 0.11694742739200592, 0.14227372407913208, -0.008126896806061268, 0.1340116560459137, -0.01337034534662962, 0.1463717818260193, -0.00014587434998247772, -0.023732943460345268, -0.013121826574206352, -0.03204740211367607, 0.19749173521995544, 0.15628322958946228, 0.037900641560554504, -0.1056276261806488, -0.08480694890022278, -0.010717657394707203, 0.1517847180366516, -0.024086585268378258, 0.08611587435007095, 0.0014321610797196627, 0.07704280316829681, -0.12221091240644455, -0.023499300703406334, 0.14656740427017212, 0.05713619664311409, -0.12616199254989624, -0.031108565628528595, -0.047981541603803635, 0.025794748216867447, -0.0641077533364296, 0.01931293122470379, 0.012186410836875439, -0.17581422626972198, -0.01851092465221882, -0.19965997338294983, -0.010611454024910927, 0.07077497243881226, 0.14221659302711487, 0.08751871436834335, -9.95511655332848e-08, 0.16705989837646484, 0.023736825212836266, -0.0030360212549567223, 0.03376993536949158, 0.05672680586576462, 0.08137568086385727, -0.0615396723151207, 0.07995396852493286, -0.07063424587249756, 0.1722327023744583, -0.03842568024992943, 0.07409735023975372, -0.17252062261104584, -0.09628713130950928, -0.07572263479232788, -0.060101233422756195, -0.09068747609853745, -0.06459210813045502, 0.015487625263631344, -0.1283332258462906, -0.11729446053504944, 0.1619725376367569, 0.061272554099559784, -0.03989214077591896, -0.12127242982387543, -0.006832481361925602, 0.00787421129643917, 0.05355609208345413, 0.12119937688112259, 0.008366785943508148, 0.0715022012591362, 0.054044123739004135, 0.04475780948996544, 0.042290400713682175, -0.010501457378268242, -0.19004307687282562, -0.02402055263519287, 0.19860641658306122, -0.05417599156498909, 0.19590847194194794, 0.004326677415519953, -0.04895257577300072, -0.1334146410226822, -0.02005317434668541, -0.030144091695547104, -0.02843651920557022, -0.15570300817489624, -0.054421693086624146, 0.119577556848526, -0.10788403451442719, 0.0910026878118515, 0.01008165255188942, -0.06284148246049881, -0.009119154885411263, 0.008617199026048183, -0.013438631780445576, -0.1253097951412201, -0.07647634297609329, -0.12822981178760529, -0.00028652066248469055, 0.07607077062129974, -0.45449456572532654, -0.07371337711811066, 0.1794099360704422], "changes": {"1wk": 4.862835004839718, "1mo": -18.952623079868435}}, {"text": "ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates Zacks Equity Research Wed, Nov 13, 2024, 3:40 PM 3 min read In This Article: SPRY -5.45% ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.16 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -11.11%. A quarter ago, it was expected that this company would post a loss of $0.12 per share when it actually produced a loss of $0.13, delivering a surprise of -8.33%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. ARS Pharmaceuticals, Inc. , which belongs to the Zacks Medical - Drugs industry, posted revenues of $2.07 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 8.50%. This compares to zero revenues a year ago. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. ARS Pharmaceuticals, Inc. Shares have added about 203.1% since the beginning of the year versus the S&P 500's gain of 25.5%. What's Next for ARS Pharmaceuticals, Inc. While ARS Pharmaceuticals, Inc. Has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for ARS Pharmaceuticals, Inc. Favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.22 on $6.41 million in revenues for the coming quarter and -$0.64 on $7.68 million in revenues for the current fiscal year. Story Continues Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 25% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, 4D Molecular Therapeutics, Inc. (FDMT), has yet to report results for the quarter ended September 2024. This company is expected to post quarterly loss of $0.67 per share in its upcoming report, which represents a year-over-year change of -179.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. 4D Molecular Therapeutics, Inc.'s revenues are expected to be $1.27 million, down 93.7% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ARS Pharmaceuticals, Inc. (SPRY) : Free Stock Analysis Report 4D Molecular Therapeutics, Inc. (FDMT) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "FDMT", "date": "2024-11-13T12:40:04+00:00", "sentiment": {"score": -0.10608287900686264, "confidence": 0.22656455636024475, "probabilities": {"positive": 0.12048167735338211, "negative": 0.22656455636024475, "neutral": 0.6529537439346313}}, "embedding": [-0.10962162911891937, 0.02911240980029106, -0.04126196727156639, 0.025034118443727493, 0.012042376212775707, -0.03715464100241661, 0.044064924120903015, 0.0882539227604866, 0.317155122756958, 0.12591513991355896, -0.06094337999820709, 0.1651354730129242, 0.09413802623748779, -0.021653588861227036, -0.11877711117267609, -0.06515562534332275, -0.025804802775382996, -0.04855277016758919, -0.14023727178573608, 0.042352933436632156, -0.05498114228248596, 0.03518836200237274, 0.13849827647209167, 0.07995376735925674, 0.03887149691581726, 0.0833454504609108, -0.05185907334089279, 0.04575708135962486, -0.23755010962486267, -0.07323870062828064, -0.008963296189904213, 0.10528703033924103, 0.10439702868461609, -0.1379668414592743, -0.04832145571708679, 0.011893372982740402, -0.048859357833862305, 0.16276857256889343, 0.16343337297439575, -0.04706738144159317, -0.031173573806881905, 0.018850388005375862, -0.1523326188325882, -0.019576914608478546, -0.07172976434230804, -0.20749565958976746, -0.04934297129511833, -0.037136368453502655, -0.024034012109041214, 0.12014509737491608, -0.19323861598968506, -0.047425489872694016, 0.05034910514950752, 0.004345223307609558, -0.057330433279275894, 0.01523582637310028, -0.14947789907455444, -0.03282846510410309, 0.00805177167057991, 0.09651802480220795, 0.049787648022174835, 0.05774887651205063, 0.04901490360498428, 0.05198976770043373, 0.17131973803043365, -0.006464987061917782, 0.17950144410133362, 0.036135558038949966, -0.14495977759361267, 0.08312658965587616, 0.061512261629104614, -0.06995093077421188, -0.08492791652679443, -0.028098829090595245, -0.11775630712509155, 0.03656933456659317, 0.15154066681861877, 0.1115044504404068, 0.09346601366996765, -0.09620606154203415, 0.06741657108068466, -0.005764623172581196, -0.08887609839439392, -0.04592228680849075, -0.033906564116477966, 0.015240862965583801, 0.1790212094783783, 0.09414364397525787, 0.0473392978310585, -0.010837245732545853, -0.03290240466594696, -0.030791237950325012, 0.0027105226181447506, -0.07148091495037079, 0.16369611024856567, 0.0679507851600647, -0.08372361958026886, -0.0958385020494461, 0.0025294222868978977, 0.08022011816501617, 0.12357692420482635, 0.12663359940052032, -0.15142495930194855, -0.13200253248214722, 0.03933224081993103, -0.15436825156211853, 0.0442470908164978, -0.013233199715614319, 0.023678656667470932, 0.11518695950508118, -0.04987618327140808, 0.0990016981959343, -0.10984395444393158, -0.06154509633779526, 0.004859469830989838, 0.018421433866024017, -0.01966373436152935, 0.12023330479860306, 0.10280326753854752, 0.0625552237033844, 0.02280505560338497, 0.14265510439872742, 0.002790686674416065, 0.010611586272716522, 0.025406718254089355, 0.07471871376037598, -0.18975324928760529, 4.8562588327826675e-33, 0.07730306684970856, 0.13517892360687256, 0.059806566685438156, -0.05082549899816513, -0.08630454540252686, -0.014110475778579712, 0.011047267355024815, -0.0018137730658054352, -0.03995238617062569, -0.08196184784173965, -0.16140958666801453, 0.03378953039646149, -0.03704896941781044, -0.1395331621170044, 0.018765807151794434, -0.1203744038939476, 0.013394948095083237, 0.10416534543037415, 0.0783214122056961, -0.058093249797821045, -0.09494343400001526, -0.047988444566726685, -0.020175572484731674, -0.011663822457194328, 0.07230062782764435, 0.06467944383621216, -0.06969936937093735, 0.05014215409755707, -0.1724419891834259, -0.010717714205384254, 0.04406899958848953, 0.08588993549346924, -0.01896277442574501, -0.2376796007156372, -0.08777597546577454, -0.13597184419631958, -0.06756278872489929, 0.023030780255794525, 0.15747086703777313, 0.03489253297448158, -0.11183194816112518, 0.07290880382061005, -0.14056582748889923, -0.11368458718061447, -0.06821832060813904, 0.0797203928232193, -0.08872121572494507, 0.07423140108585358, 0.02466367557644844, -0.0290700551122427, -0.03291122615337372, -0.014899887144565582, 0.03215446323156357, -0.03485116735100746, -0.08822537958621979, 0.03420213237404823, -0.08318832516670227, -0.20175865292549133, 0.07013359665870667, 0.21320264041423798, 0.11386828124523163, 0.21307367086410522, 0.03289048373699188, -0.004147891886532307, -0.1970093995332718, 0.15501061081886292, -0.01826905459165573, 0.07399607449769974, -0.062102459371089935, 0.19833487272262573, 0.007674270309507847, -0.02124759554862976, 0.12739194929599762, -0.07846847176551819, 0.14340758323669434, -0.03069375269114971, -0.07618147879838943, -0.07094220072031021, 0.11482270061969757, 0.11480948328971863, 0.02647762931883335, -0.08108040690422058, 0.005833602976053953, -0.021369483321905136, -0.0100499102845788, -0.022401990368962288, 0.05812505632638931, 0.030401155352592468, 0.010381467640399933, -0.0287864301353693, 0.02906368486583233, -0.15236236155033112, -0.1726561188697815, 0.10853518545627594, 0.016053296625614166, -5.85323526464939e-33, -0.002002446912229061, 0.0560094490647316, -0.03530023247003555, -0.03079690784215927, -0.10805430263280869, -0.03030107542872429, 0.146859809756279, 0.10076351463794708, -0.013581238687038422, -0.012879569083452225, 0.00860506109893322, 0.06348191946744919, -0.1286405771970749, 0.025870583951473236, -0.07376401126384735, 0.015096183866262436, 0.13050006330013275, -0.18691956996917725, 0.1269748955965042, 0.009264674037694931, 0.06237446889281273, 0.15808990597724915, -0.11674760282039642, 0.10289302468299866, -0.003688790136948228, 0.06842280179262161, 0.0817587822675705, 0.20049253106117249, -0.01473432220518589, -0.08899884670972824, 0.03612399101257324, -0.04971116781234741, -0.18130233883857727, 0.05548534914851189, -0.033806342631578445, -0.058531809598207474, -0.04589250683784485, -0.17322078347206116, -0.07993723452091217, -0.049134742468595505, 0.12566667795181274, 0.03594695404171944, 0.009265339002013206, 0.10239162296056747, 0.11022908985614777, 0.006903164088726044, 0.027607813477516174, 0.08825739473104477, 0.25163114070892334, 0.02989487536251545, -0.009602867066860199, 0.02047509141266346, -0.04613690823316574, 0.16706261038780212, -0.10680050402879715, 0.03985493257641792, -0.11701475828886032, 0.051114678382873535, -0.12512099742889404, 0.0413418672978878, -0.02092774212360382, 0.18741807341575623, 0.01259768195450306, 0.02374849282205105, -0.038860443979501724, 0.05432918667793274, -0.003800969570875168, -0.056969333440065384, 0.08069859445095062, -0.17185887694358826, 0.06384368985891342, -0.13406167924404144, 0.08285335451364517, -0.21525564789772034, -0.005943292286247015, 0.25102856755256653, -0.09302639961242676, -0.18624001741409302, -0.11746910959482193, 0.01549963653087616, 0.13292774558067322, 0.08739867061376572, -0.0007758769206702709, 0.04529193043708801, -0.19872863590717316, 0.19014477729797363, 0.04979371279478073, -0.05526140704751015, -0.061180830001831055, -0.037277862429618835, -0.071990966796875, -0.21548813581466675, -0.1631467640399933, 0.00935675110667944, 0.00732499361038208, -9.98816602759689e-08, 0.02238883636891842, -0.039176732301712036, 0.1088731586933136, -0.03084290400147438, 0.11654958128929138, -0.028792835772037506, 0.052981793880462646, -0.033093880861997604, 0.18795952200889587, 0.08824004977941513, 0.009254856035113335, -0.018260134384036064, -0.178097665309906, 0.10246552526950836, -0.1510646939277649, 0.05119616538286209, -0.11575841158628464, 0.06330196559429169, -0.001956535503268242, -0.20445021986961365, -0.15100282430648804, 0.069069042801857, 0.06454138457775116, -0.1373698115348816, 0.0901549905538559, -0.09233072400093079, -0.07585827261209488, -0.06583970785140991, -0.0070809610188007355, 0.0357186496257782, 0.06662759184837341, -0.1231265664100647, 0.18505840003490448, 0.1030798926949501, 0.0024400297552347183, -0.09115365147590637, 0.07604490220546722, 0.06033707410097122, 0.09725077450275421, 0.03947849199175835, -0.10260017216205597, -0.053979068994522095, -0.005190919619053602, 0.017507899552583694, -0.1125708669424057, -0.09967026859521866, -0.20292574167251587, 0.07151694595813751, 0.0378560908138752, -0.27857673168182373, 0.20202991366386414, -0.023327264934778214, 0.0298150647431612, 0.04704243317246437, 0.1391855925321579, 0.04383600130677223, -0.19269675016403198, -0.054708726704120636, -0.12461013346910477, 0.012093348428606987, 0.13551826775074005, -0.24772867560386658, 0.04235483333468437, 0.07554427534341812], "changes": {"1wk": 12.451362300871011, "1mo": -10.76523890531053}}, {"text": "Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates Zacks Equity Research Tue, Nov 12, 2024, 5:10 PM 3 min read In This Article: HRTX -0.59% Heron Therapeutics (HRTX) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this pharmaceutical company would post a loss of $0.04 per share when it actually produced a loss of $0.06, delivering a surprise of -50%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Heron Therapeutics , which belongs to the Zacks Medical - Drugs industry, posted revenues of $32.81 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 9.86%. This compares to year-ago revenues of $31.43 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Heron Therapeutics shares have added about 8.2% since the beginning of the year versus the S&P 500's gain of 25.8%. What's Next for Heron Therapeutics? While Heron Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Heron Therapeutics: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.01 on $41.15 million in revenues for the coming quarter and -$0.08 on $148.3 million in revenues for the current fiscal year. Story Continues Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 27% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, 4D Molecular Therapeutics, Inc. (FDMT), is yet to report results for the quarter ended September 2024. This company is expected to post quarterly loss of $0.67 per share in its upcoming report, which represents a year-over-year change of -179.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. 4D Molecular Therapeutics, Inc.'s revenues are expected to be $1.27 million, down 93.7% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Heron Therapeutics, Inc. (HRTX) : Free Stock Analysis Report 4D Molecular Therapeutics, Inc. (FDMT) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "FDMT", "date": "2024-11-12T14:10:03+00:00", "sentiment": {"score": -0.025813817977905273, "confidence": 0.2615787386894226, "probabilities": {"positive": 0.23576492071151733, "negative": 0.2615787386894226, "neutral": 0.5026564002037048}}, "embedding": [-0.08599905669689178, -0.028707275167107582, -0.027903813868761063, 0.007321771699935198, -0.07834599912166595, -0.0403808057308197, 0.03754749521613121, 0.16315026581287384, 0.22788961231708527, 0.05273795127868652, -0.12803371250629425, 0.10766908526420593, -0.009431237354874611, 0.011102749966084957, -0.12649719417095184, 0.04946644604206085, 0.03267476707696915, -0.04094215855002403, -0.05447172373533249, 0.05684858560562134, -0.14717698097229004, 0.042768578976392746, 0.08550790697336197, 0.11965082585811615, 0.04803910851478577, 0.054580189287662506, -0.12120287120342255, 0.011148941703140736, -0.17217351496219635, -0.1027541309595108, -0.03641778603196144, 0.1755039393901825, 0.09354479610919952, -0.17289388179779053, -0.05457814410328865, 0.009715337306261063, -0.04012059047818184, 0.06120682507753372, 0.0003748629242181778, 0.008600058034062386, -0.016141634434461594, 0.026487082242965698, -0.13253998756408691, 0.012956085614860058, -0.10505904257297516, -0.19661845266819, -0.04879998043179512, 0.012061968445777893, 0.06338533014059067, 0.09999498724937439, -0.1929049789905548, -0.15266971290111542, 0.01308872178196907, 0.059805817902088165, -0.10281265527009964, 0.042801495641469955, -0.10196144878864288, -0.06461897492408752, 0.00354755949229002, 0.04216579347848892, 0.005260434001684189, 0.07503992319107056, -0.02328597381711006, 0.07074366509914398, 0.1795666664838791, 0.018909454345703125, 0.03264187276363373, 0.007515648379921913, -0.056923091411590576, 0.017396336421370506, 0.07562674582004547, -0.06887777894735336, -0.14520347118377686, -0.03266438841819763, -0.15369576215744019, 0.06120462343096733, 0.19162514805793762, 0.11975456029176712, 0.12348881363868713, -0.07283807545900345, 0.04607561603188515, -0.017436731606721878, 0.000510666985064745, -0.05017782375216484, 0.02098454162478447, 0.045551709830760956, 0.11534163355827332, 0.18219295144081116, 0.05813293904066086, -0.029830165207386017, 0.022246405482292175, -0.0238642655313015, -0.06632381677627563, -0.11211572587490082, 0.0974586233496666, -0.0003525451757013798, -0.09882710129022598, -0.033637791872024536, 0.011153380386531353, 0.08891015499830246, 0.11792775988578796, 0.10227115452289581, -0.11110302060842514, -0.1691949963569641, 0.06254532933235168, -0.10544204711914062, 0.11879554390907288, -0.012282371520996094, 0.04767490178346634, 0.06410016864538193, -0.10871115326881409, 0.0950905829668045, -0.10818177461624146, 0.04542209208011627, -0.09928363561630249, 0.07182344794273376, -0.06151939928531647, 0.052653051912784576, 0.12834806740283966, 0.09216682612895966, 0.04945043846964836, 0.06844907999038696, 0.01592293754220009, -0.0614074245095253, -0.00028290762566030025, 0.07118245959281921, -0.21556298434734344, 7.404920868513426e-33, 0.05593639612197876, 0.011016792617738247, 0.10129238665103912, -0.06312675029039383, 0.020358072593808174, -0.013351229950785637, 0.003107059746980667, -0.060254693031311035, -0.02941499650478363, -0.0968589335680008, -0.19581958651542664, -0.0018134769052267075, 0.003856802824884653, -0.08450059592723846, 0.03274111822247505, -0.09927281737327576, -0.0076498729176819324, 0.08794662356376648, 0.01003770250827074, -0.12106230854988098, -0.09735071659088135, 0.04460353031754494, -0.10726465284824371, -0.0003630570136010647, -0.0299239419400692, 0.015550190582871437, -0.12514261901378632, 0.06250917166471481, -0.10107415914535522, 0.04795760661363602, -0.039396289736032486, -0.03913004323840141, 0.0177411250770092, -0.18445491790771484, -0.08287233114242554, -0.050268009305000305, -0.0518738217651844, -0.08229280263185501, 0.17369720339775085, 0.0680508017539978, -0.029643340036273003, 0.15959227085113525, -0.08437182754278183, -0.1003100574016571, -0.0010538380593061447, 0.051622938364744186, -0.07067863643169403, 0.024961158633232117, -0.06141884624958038, -0.033375293016433716, -0.058469224721193314, 0.011194887571036816, -0.01030704565346241, -0.035769883543252945, -0.0629335567355156, 0.06169504299759865, -0.10037495195865631, -0.1129717081785202, 0.005646985024213791, 0.21770867705345154, 0.10700032114982605, 0.19437047839164734, 0.0063861822709441185, -0.046350885182619095, -0.13317938148975372, 0.15768136084079742, -0.0037813475355505943, -0.029611051082611084, -0.11745311319828033, 0.16946351528167725, -0.01530733983963728, -0.01336508896201849, 0.1702795773744583, -0.05544615909457207, 0.15300016105175018, -0.07166425883769989, 0.05295613408088684, -0.025560125708580017, 0.11570984125137329, 0.05145347863435745, 0.043893493711948395, -0.022066615521907806, 0.01632591150701046, 0.05767585337162018, 0.0074547771364450455, -0.10408077389001846, 0.0788513571023941, 0.011885369196534157, -0.09306815266609192, -0.006898406893014908, 0.022706512361764908, -0.09878533333539963, -0.12859655916690826, 0.08893238753080368, 0.04160407930612564, -8.192718080651322e-33, -0.0637434646487236, 0.09873396903276443, 0.030916966497898102, -0.09111443161964417, -0.08387333154678345, 0.022348087280988693, 0.047768935561180115, 0.09799163788557053, 0.055582329630851746, -0.052659377455711365, 0.029002878814935684, 0.09245538711547852, -0.1482621133327484, -0.011171993799507618, -0.11474638432264328, 0.025922507047653198, 0.0794883444905281, -0.1729547530412674, -0.002372408052906394, -0.050867483019828796, 0.041810549795627594, 0.18346263468265533, -0.04833512380719185, 0.10937228053808212, 0.04232761263847351, 0.042811986058950424, 0.04947175458073616, 0.14164260029792786, 0.028439246118068695, -0.09200824052095413, -0.028617091476917267, -0.08731567114591599, -0.18068574368953705, 0.06053059920668602, -0.01863854192197323, -0.03567830100655556, 0.06836159527301788, -0.16140758991241455, -0.010196032002568245, -0.02823908068239689, 0.1669284999370575, -0.027789775282144547, 0.03479120135307312, 0.010290137492120266, 0.12008538097143173, 0.06585212051868439, 0.03706098720431328, -0.02081548422574997, 0.15627121925354004, -0.002267220290377736, -0.002279476262629032, -0.05910111591219902, -0.03622165322303772, 0.18906325101852417, -0.07941025495529175, -0.024239610880613327, -0.038381267338991165, -0.02480226755142212, -0.11414797604084015, -0.055850040167570114, 0.02767912670969963, 0.1748659610748291, -0.01150071807205677, 0.06781194359064102, 0.0011031925678253174, 0.06396827101707458, 0.006118363700807095, -0.08829245716333389, 0.011486617848277092, -0.12989073991775513, -0.032656438648700714, -0.06238960847258568, 0.04866278916597366, -0.10558684170246124, -0.030293840914964676, 0.2392856776714325, -0.009312061592936516, -0.25934460759162903, -0.08429991453886032, -0.05815126746892929, 0.06286323070526123, 0.01078642625361681, 0.00885919388383627, 0.006395081058144569, -0.04886598140001297, 0.13478900492191315, 0.07191102206707001, -0.017631787806749344, -0.04019986093044281, -0.004289327189326286, -0.04061025008559227, -0.18918630480766296, -0.16427981853485107, 0.08992107212543488, 0.10751551389694214, -1.0011942208620894e-07, 0.07363355904817581, -0.04566902294754982, 0.014041871763765812, -0.021946333348751068, 0.0543401837348938, 0.0012381859123706818, -0.005915726535022259, 0.014839556068181992, 0.11316825449466705, 0.18479815125465393, 0.013034461066126823, -0.003930508159101009, -0.1836281716823578, 0.0012542814947664738, -0.14164623618125916, 0.07033950090408325, -0.07329891622066498, 0.020371071994304657, -0.030071405693888664, -0.17347773909568787, -0.10345436632633209, 0.11276611685752869, 0.2227887511253357, -0.1085256040096283, 0.05596581846475601, -0.10534847527742386, -0.057055503129959106, -0.014470909722149372, -0.0015682463999837637, 0.06871161609888077, 0.11951163411140442, 0.0023681148886680603, 0.07829084247350693, 0.10240185260772705, -0.010385949164628983, -0.15366025269031525, 0.05803132802248001, 0.0887942984700203, 0.06956101953983307, 0.11730031669139862, -0.0335637703537941, -0.015360185876488686, -0.01652689278125763, 0.027146805077791214, 0.03571012616157532, -0.06635752320289612, -0.03878229856491089, 0.07499673962593079, 0.046567440032958984, -0.26775380969047546, 0.2463148683309555, -0.030344044789671898, 0.07898645102977753, -0.014987967908382416, 0.02797466143965721, 0.10606729984283447, -0.17016860842704773, -0.06517556309700012, -0.1309729963541031, -0.045899227261543274, 0.10566174238920212, -0.21686971187591553, 0.1101178526878357, 0.14186982810497284], "changes": {"1wk": 5.717913796807748, "1mo": -12.325283409108232}}, {"text": "Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates Zacks Equity Research Fri, Nov 8, 2024, 1:40 AM 3 min read In This Article: NKTR -2.22% Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 21.74%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.21 per share when it actually produced a loss of $0.25, delivering a surprise of -19.05%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Nektar , which belongs to the Zacks Medical - Drugs industry, posted revenues of $24.12 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 55.24%. This compares to year-ago revenues of $24.14 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Nektar shares have added about 146% since the beginning of the year versus the S&P 500's gain of 24.3%. What's Next for Nektar? While Nektar has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Nektar: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.22 on $17.04 million in revenues for the coming quarter and -$0.85 on $77.84 million in revenues for the current fiscal year. Story Continues Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 33% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, 4D Molecular Therapeutics, Inc. (FDMT), has yet to report results for the quarter ended September 2024. This company is expected to post quarterly loss of $0.67 per share in its upcoming report, which represents a year-over-year change of -179.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. 4D Molecular Therapeutics, Inc.'s revenues are expected to be $1.27 million, down 93.7% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Nektar Therapeutics (NKTR) : Free Stock Analysis Report 4D Molecular Therapeutics, Inc. (FDMT) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "FDMT", "date": "2024-11-07T22:40:08+00:00", "sentiment": {"score": 0.01165740191936493, "confidence": 0.14565566182136536, "probabilities": {"positive": 0.14565566182136536, "negative": 0.13399825990200043, "neutral": 0.7203460931777954}}, "embedding": [-0.15303340554237366, 0.10083751380443573, 0.0014770105481147766, 0.07451681792736053, -0.08835440874099731, -0.06526682525873184, -0.0850977897644043, 0.16569213569164276, 0.22244857251644135, 0.08577616512775421, -0.15882042050361633, 0.06286180019378662, 0.027010569348931313, -0.024906005710363388, -0.11881259083747864, -0.03409523516893387, 0.050992611795663834, -0.049159612506628036, -0.15544700622558594, 0.04355410113930702, -0.058805689215660095, 0.06316714733839035, 0.07526227086782455, -0.006656034849584103, 0.05888146162033081, -0.02127334102988243, -0.04695965349674225, -0.060910679399967194, -0.18590116500854492, -0.128738671541214, -0.03808048740029335, 0.055030569434165955, 0.023405324667692184, -0.06359253823757172, -0.031947847455739975, -0.05402374267578125, -0.11893308907747269, 0.17156101763248444, 0.019515767693519592, 0.09352853149175644, -0.044767580926418304, 0.008880045264959335, -0.17047017812728882, 0.001103455200791359, -0.07330171763896942, -0.15575802326202393, -0.12695354223251343, -0.10130055248737335, 0.053029268980026245, 0.11918915808200836, -0.27715742588043213, -0.08150194585323334, 0.02703695558011532, 0.11591885983943939, 0.009232286363840103, 0.03036615438759327, -0.1136426329612732, -0.08310559391975403, 0.0562526099383831, 0.12279848754405975, 0.08240360021591187, 0.008561440743505955, 0.00596265122294426, 0.004591099917888641, 0.24182705581188202, 0.0010409164242446423, 0.07169181853532791, 0.06324100494384766, -0.09635158628225327, 0.10241270065307617, 0.1353067010641098, -0.054496489465236664, -0.06529491394758224, -0.08732116967439651, -0.22308003902435303, -0.016458049416542053, 0.0917363315820694, 0.144693061709404, 0.121833935379982, -0.029244421049952507, 0.1309327781200409, 0.02017858810722828, -0.05343332886695862, -0.03235864266753197, 0.04229322075843811, 0.017683062702417374, 0.04401081055402756, 0.10934723913669586, 0.04792410880327225, 0.0964435264468193, 0.05397831276059151, -0.009135682135820389, 0.007017661817371845, -0.08758614957332611, 0.06079700589179993, -0.03334059566259384, -0.07617080211639404, -0.06350725889205933, 0.07165464758872986, 0.07580342888832092, 0.18564720451831818, 0.12620431184768677, -0.1313987374305725, -0.12996552884578705, -0.019498584792017937, -0.15361803770065308, 0.17275485396385193, -0.05988093838095665, 0.09398218989372253, 0.23230135440826416, -0.10908745229244232, 0.10803672671318054, -0.1719498336315155, -0.03725776821374893, -0.05668244510889053, 0.07564802467823029, -0.01544472761452198, 0.1716756522655487, 0.1149526834487915, 0.11968361586332321, 0.08605701476335526, 0.058942005038261414, -0.031908296048641205, -0.013905984349548817, 0.06446190178394318, 0.16213300824165344, -0.14687702059745789, 8.556714314487259e-33, 0.06266813725233078, 0.018224235624074936, 0.06285463273525238, 0.003674698993563652, -0.06759238243103027, 0.05012664198875427, -0.07335770130157471, -0.07761675119400024, -0.021448567509651184, -0.19451749324798584, -0.16372595727443695, 0.03534269332885742, -0.10441653430461884, -0.022633438929915428, -0.03730306029319763, -0.07146299630403519, -0.10639843344688416, 0.00791236013174057, -0.050464928150177, 0.051048535853624344, 0.05795551836490631, 0.019602574408054352, -0.0805031806230545, 0.0033596204593777657, -0.05975799262523651, -0.02539948746562004, -0.15681129693984985, 0.054939571768045425, -0.22896060347557068, 0.00398412998765707, -0.051938798278570175, -0.013714289292693138, 0.02933095209300518, -0.12623892724514008, -0.11644670367240906, -0.0996331050992012, -0.07462146133184433, -0.003735022619366646, 0.1099463552236557, -0.016556084156036377, -0.12453305721282959, 0.12368391454219818, -0.17192819714546204, -0.19000446796417236, -0.04849616438150406, 0.10368573665618896, -0.05124986171722412, 0.0366746261715889, 0.02150203101336956, -0.034978631883859634, -0.025477901101112366, 0.01898907497525215, -0.053186096251010895, -0.04371514171361923, -0.01183662936091423, 0.026886172592639923, -0.06096992269158363, -0.18304049968719482, 0.11266782879829407, 0.13536404073238373, 0.09804538637399673, 0.18893839418888092, 0.0771716982126236, -0.06476394087076187, -0.1161734014749527, 0.17317157983779907, -0.04683567211031914, 0.10800325870513916, -0.0892506092786789, 0.1313677430152893, -0.043555546551942825, 0.06839394569396973, 0.12117726355791092, -0.028095059096813202, 0.1093699112534523, -0.10110053420066833, -0.03329535946249962, -0.01644013077020645, 0.04182920232415199, 0.08629520237445831, 0.14666523039340973, -0.09075497835874557, 0.03994891047477722, -0.012267015874385834, 0.06467320770025253, -0.11422517895698547, 0.06057097762823105, 0.009448859840631485, 0.01306955423206091, -0.023177819326519966, 0.06912797689437866, -0.14082786440849304, -0.19976937770843506, 0.07057134807109833, -0.0020392276346683502, -9.408542173282384e-33, -0.008926941081881523, 0.09166334569454193, -0.0017521223053336143, 0.011525479145348072, -0.028090719133615494, 0.015255199745297432, 0.11151951551437378, 0.09169673919677734, -0.0007168557494878769, -0.048644572496414185, 0.021429793909192085, 0.12073299288749695, -0.05073843523859978, 0.08810003101825714, -0.016628440469503403, -0.023364495486021042, 0.033154070377349854, -0.05452944338321686, 0.10779392719268799, -0.1442151814699173, 0.0346689373254776, 0.1797286868095398, -0.12547865509986877, 0.10044435411691666, 0.03674861043691635, 0.0788160040974617, 0.0100306561216712, 0.21963045001029968, -0.0506734699010849, -0.07906506210565567, 0.057046324014663696, -0.046324223279953, -0.1841874122619629, 0.034541405737400055, 0.018280507996678352, -0.03989244997501373, -0.02121419832110405, -0.11068110167980194, -0.019408315420150757, -0.1244598776102066, 0.17311835289001465, 0.062454499304294586, 0.05558505654335022, 0.04383818060159683, 0.029390964657068253, -0.02183631621301174, 0.036606237292289734, -0.0032307645305991173, 0.22167649865150452, -0.05615030974149704, 0.05155666172504425, 0.009923862293362617, -0.08525361120700836, 0.18921490013599396, -0.06459853053092957, 0.08280211687088013, -0.0702035203576088, -0.025944136083126068, -0.06767839938402176, 0.06042557954788208, -0.04073668271303177, 0.14396704733371735, 0.0007598958909511566, -0.03007577918469906, -0.03939703106880188, 0.041138939559459686, 0.0884597972035408, 0.017218973487615585, 0.051211416721343994, -0.016034826636314392, 0.02123917266726494, 0.00038913264870643616, 0.12525708973407745, -0.15270383656024933, -0.018638843670487404, 0.2260783314704895, -0.04161103069782257, -0.13047784566879272, -0.14323800802230835, -0.040376707911491394, 0.06440053135156631, 0.01865296997129917, 0.03860073909163475, -0.026634179055690765, -0.14231449365615845, 0.15293282270431519, 0.07621971517801285, -0.04232294112443924, -0.058811575174331665, -0.011095598340034485, -0.08020287752151489, -0.18009084463119507, -0.21439696848392487, 0.14747348427772522, 0.1000971794128418, -9.998620953410864e-08, 0.062114499509334564, -0.05898032709956169, 0.04753658547997475, -0.010364271700382233, 0.13757215440273285, -0.0478605218231678, -0.00804111734032631, -0.04008208215236664, 0.07524386048316956, 0.14660054445266724, 0.10815632343292236, 0.04852092266082764, -0.23648348450660706, 0.02257547713816166, -0.14806413650512695, 0.0720679759979248, -0.07407201081514359, 0.08434552699327469, 0.027604438364505768, -0.10446802526712418, -0.05240222066640854, 0.033250853419303894, 0.04839733615517616, -0.1332193911075592, 0.012799486517906189, -0.03148553520441055, -0.009814422577619553, 0.04703356325626373, 0.1152123436331749, -0.08766168355941772, 0.0003344854339957237, -0.03733471781015396, 0.09429837763309479, 0.09176420420408249, -0.049488481134176254, -0.13119544088840485, -0.021852869540452957, 0.042709652334451675, 0.08664900064468384, 0.03499230742454529, -0.005618975963443518, -0.02413201332092285, 0.028598293662071228, 0.05637623742222786, -0.08989648520946503, -0.13483402132987976, -0.19930170476436615, 0.010796843096613884, 0.0010838191956281662, -0.21695812046527863, 0.1347198784351349, -0.011747989803552628, -0.0025109252892434597, 0.10446962714195251, 0.13323469460010529, 0.054610975086688995, -0.16868305206298828, 0.04893528297543526, -0.20935872197151184, -0.027142394334077835, 0.08332327008247375, -0.25660836696624756, 0.052985500544309616, 0.1636095643043518], "changes": {"1wk": -3.1400879660925, "1mo": -11.231882346992569}}]